https://www.gsk.com/en-gb/ https://www.gsk.com/en-gb/about-us/ https://www.gsk.com/en-gb/about-us/pharmaceuticals/ https://www.gsk.com/en-gb/about-us/vaccines/ https://www.gsk.com/en-gb/about-us/consumer-healthcare/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/emma-walmsley/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/iain-mackay/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/dr-hal-barron/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/roger-connor/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/diana-conrad/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/james-ford/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/nick-hirons/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/sally-jackson/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/brian-mcnamara/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/luke-miels/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/david-redfern/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/regis-simard/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/karenann-terrell/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/phil-thomson/ https://www.gsk.com/en-gb/about-us/corporate-executive-team/deborah-waterhouse/ https://www.gsk.com/en-gb/about-us/board-of-directors/ https://www.gsk.com/en-gb/about-us/board-of-directors/sir-jonathan-symonds-cbe/ https://www.gsk.com/en-gb/about-us/board-of-directors/emma-walmsley/ https://www.gsk.com/en-gb/about-us/board-of-directors/iain-mackay/ https://www.gsk.com/en-gb/about-us/board-of-directors/dr-hal-barron/ https://www.gsk.com/en-gb/about-us/board-of-directors/charles-bancroft/ https://www.gsk.com/en-gb/about-us/board-of-directors/manvinder-singh-vindi-banga/ https://www.gsk.com/en-gb/about-us/board-of-directors/dr-vivienne-cox/ https://www.gsk.com/en-gb/about-us/board-of-directors/lynn-elsenhans/ https://www.gsk.com/en-gb/about-us/board-of-directors/dr-laurie-glimcher/ https://www.gsk.com/en-gb/about-us/board-of-directors/dr-jesse-goodman/ https://www.gsk.com/en-gb/about-us/board-of-directors/judy-lewent/ https://www.gsk.com/en-gb/about-us/board-of-directors/urs-rohner/ https://www.gsk.com/en-gb/about-us/board-of-directors/independence-of-non-executive-directors/ https://www.gsk.com/en-gb/about-us/board-of-directors/role-of-the-board/ https://www.gsk.com/en-gb/about-us/board-of-directors/the-roles-of-our-chairman-and-chief-executive-officer/ https://www.gsk.com/en-gb/about-us/board-of-directors/directors-contracts/ https://www.gsk.com/en-gb/about-us/board-of-directors/membership-of-board-committees/ https://www.gsk.com/en-gb/about-us/our-history/ https://www.gsk.com/en-gb/about-us/our-history/innovative-entrepreneurs-1715-1891/ https://www.gsk.com/en-gb/about-us/our-history/going-global-1892-1918/ https://www.gsk.com/en-gb/about-us/our-history/building-brands-1919-1949/ https://www.gsk.com/en-gb/about-us/our-history/creating-the-gsk-of-today-1950-1999/ https://www.gsk.com/en-gb/about-us/our-history/gsk-today-2000-present/ https://www.gsk.com/en-gb/about-us/our-history/gsk-heritage-archives/ https://www.gsk.com/en-gb/about-us/governance/ https://www.gsk.com/en-gb/about-us/governance/board-committees/ https://www.gsk.com/en-gb/about-us/governance/other-committees/ https://www.gsk.com/en-gb/about-us/governance/shareholders/ https://www.gsk.com/en-gb/about-us/governance/sarbanes-oxley-act-2002/ https://www.gsk.com/en-gb/about-us/governance/global-compliance/ https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/ https://www.gsk.com/en-gb/about-us/key-facts/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/sierra-leone/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/ghana/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/mozambique/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/tanzania/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/greater-mekong-subregion/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/johari-mother-of-four/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/leonard-father-farmer-and-assistant/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/nsaje-teacher/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/johari-mother-of-two/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/jacob-tanzania-communication-and-development-centre/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/patrick-malaria-patient/ https://www.gsk.com/en-gb/about-us/comic-relief-partnership/the-race-against-malaria-handing-the-baton-to-the-next-generation/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/overview/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/meet-the-children/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/trek-for-kids/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/meet-baby-mckline-a-special-delivery-from-our-save-the-children-partnership/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/the-app-that-could-save-lives/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/a-new-response-to-humanitarian-crises/ https://www.gsk.com/en-gb/about-us/save-the-children-partnership/giving-mothers-and-babies-a-healthier-start/ https://www.gsk.com/en-gb/about-us/smile-train-partnership/ https://www.gsk.com/en-gb/products/ https://www.gsk.com/en-gb/products/our-prescription-medicines/ https://www.gsk.com/en-gb/products/our-prescription-medicines/advair/ https://www.gsk.com/en-gb/products/our-prescription-medicines/altabax/ https://www.gsk.com/en-gb/products/our-prescription-medicines/adartrel/ https://www.gsk.com/en-gb/products/our-prescription-medicines/altargo/ https://www.gsk.com/en-gb/products/our-prescription-medicines/amerge/ https://www.gsk.com/en-gb/products/our-prescription-medicines/amoxil/ https://www.gsk.com/en-gb/products/our-prescription-medicines/anectine/ https://www.gsk.com/en-gb/products/our-prescription-medicines/anoro-ellipta/ https://www.gsk.com/en-gb/products/our-prescription-medicines/augmentin/ https://www.gsk.com/en-gb/products/our-prescription-medicines/avamys/ https://www.gsk.com/en-gb/products/our-prescription-medicines/avandamet/ https://www.gsk.com/en-gb/products/our-prescription-medicines/avandaryl/ https://www.gsk.com/en-gb/products/our-prescription-medicines/avandia/ https://www.gsk.com/en-gb/products/our-prescription-medicines/avodart/ https://www.gsk.com/en-gb/products/our-prescription-medicines/bactroban/ https://www.gsk.com/en-gb/products/our-prescription-medicines/becotide/ https://www.gsk.com/en-gb/products/our-prescription-medicines/benlysta/ https://www.gsk.com/en-gb/products/our-prescription-medicines/bexxar/ https://www.gsk.com/en-gb/products/our-prescription-medicines/betnovate/ https://www.gsk.com/en-gb/products/our-prescription-medicines/breo/ https://www.gsk.com/en-gb/products/our-prescription-medicines/ceftin/ https://www.gsk.com/en-gb/products/our-prescription-medicines/combodart/ https://www.gsk.com/en-gb/products/our-prescription-medicines/coreg/ https://www.gsk.com/en-gb/products/our-prescription-medicines/coreg-cr/ https://www.gsk.com/en-gb/products/our-prescription-medicines/cutivate/ https://www.gsk.com/en-gb/products/our-prescription-medicines/daraprim/ https://www.gsk.com/en-gb/products/our-prescription-medicines/dermovate/ https://www.gsk.com/en-gb/products/our-prescription-medicines/duodart/ https://www.gsk.com/en-gb/products/our-prescription-medicines/dyazide/ https://www.gsk.com/en-gb/products/our-prescription-medicines/eumovate/ https://www.gsk.com/en-gb/products/our-prescription-medicines/flixonase/ https://www.gsk.com/en-gb/products/our-prescription-medicines/flixotide/ https://www.gsk.com/en-gb/products/our-prescription-medicines/flolan/ https://www.gsk.com/en-gb/products/our-prescription-medicines/flonase/ https://www.gsk.com/en-gb/products/our-prescription-medicines/flovent/ https://www.gsk.com/en-gb/products/our-prescription-medicines/fortum/ https://www.gsk.com/en-gb/products/our-prescription-medicines/imigran/ https://www.gsk.com/en-gb/products/our-prescription-medicines/imitrex/ https://www.gsk.com/en-gb/products/our-prescription-medicines/incruse-ellipta/ https://www.gsk.com/en-gb/products/our-prescription-medicines/integrilin/ https://www.gsk.com/en-gb/products/our-prescription-medicines/jalyn/ https://www.gsk.com/en-gb/products/our-prescription-medicines/lamictal/ https://www.gsk.com/en-gb/products/our-prescription-medicines/levitra/ https://www.gsk.com/en-gb/products/our-prescription-medicines/lovaza/ https://www.gsk.com/en-gb/products/our-prescription-medicines/malarone/ https://www.gsk.com/en-gb/products/our-prescription-medicines/mepron/ https://www.gsk.com/en-gb/products/our-prescription-medicines/mivacron/ https://www.gsk.com/en-gb/products/our-prescription-medicines/naramig/ https://www.gsk.com/en-gb/products/our-prescription-medicines/nimbex/ https://www.gsk.com/en-gb/products/our-prescription-medicines/otosporin-ear-drops/ https://www.gsk.com/en-gb/products/our-prescription-medicines/pentostam/ https://www.gsk.com/en-gb/products/our-prescription-medicines/prolia/ https://www.gsk.com/en-gb/products/our-prescription-medicines/relenza/ https://www.gsk.com/en-gb/products/our-prescription-medicines/requip/ https://www.gsk.com/en-gb/products/our-prescription-medicines/respontin-nebules/ https://www.gsk.com/en-gb/products/our-prescription-medicines/rythmol/ https://www.gsk.com/en-gb/products/our-prescription-medicines/rythmol-sr/ https://www.gsk.com/en-gb/products/our-prescription-medicines/seretide/ https://www.gsk.com/en-gb/products/our-prescription-medicines/serevent/ https://www.gsk.com/en-gb/products/our-prescription-medicines/seroxat/ https://www.gsk.com/en-gb/products/our-prescription-medicines/staxyn/ https://www.gsk.com/en-gb/products/our-prescription-medicines/tracrium/ https://www.gsk.com/en-gb/products/our-prescription-medicines/treximet/ https://www.gsk.com/en-gb/products/our-prescription-medicines/trimovate/ https://www.gsk.com/en-gb/products/our-prescription-medicines/trobalt/ https://www.gsk.com/en-gb/products/our-prescription-medicines/ultiva/ https://www.gsk.com/en-gb/products/our-prescription-medicines/valtrex/ https://www.gsk.com/en-gb/products/our-prescription-medicines/ventolin/ https://www.gsk.com/en-gb/products/our-prescription-medicines/ventolin-hfa/ https://www.gsk.com/en-gb/products/our-prescription-medicines/veramyst/ https://www.gsk.com/en-gb/products/our-prescription-medicines/volibris/ https://www.gsk.com/en-gb/products/our-prescription-medicines/wellbutrin/ https://www.gsk.com/en-gb/products/our-prescription-medicines/wellvone/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zantac/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zeffix/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zinacef/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zinnat/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zovirax/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zyban/ https://www.gsk.com/en-gb/products/our-prescription-medicines/zejula/ https://www.gsk.com/en-gb/products/our-prescription-medicines/trelegy/ https://www.gsk.com/en-gb/products/our-prescription-medicines/blenrep/ https://www.gsk.com/en-gb/products/our-prescription-medicines/dectova/ https://www.gsk.com/en-gb/products/our-vaccines/ https://www.gsk.com/en-gb/products/our-vaccines/ambirix/ https://www.gsk.com/en-gb/products/our-vaccines/bexsero/ https://www.gsk.com/en-gb/products/our-vaccines/boostrix/ https://www.gsk.com/en-gb/products/our-vaccines/cervarix/ https://www.gsk.com/en-gb/products/our-vaccines/encepur/ https://www.gsk.com/en-gb/products/our-vaccines/engerix-b/ https://www.gsk.com/en-gb/products/our-vaccines/fendrix/ https://www.gsk.com/en-gb/products/our-vaccines/fluarix-trivalent-fluarix-quadrivalent/ https://www.gsk.com/en-gb/products/our-vaccines/flulaval-trivalent-flulaval-quadrivalent/ https://www.gsk.com/en-gb/products/our-vaccines/havrix/ https://www.gsk.com/en-gb/products/our-vaccines/hepatyrix/ https://www.gsk.com/en-gb/products/our-vaccines/hiberix/ https://www.gsk.com/en-gb/products/our-vaccines/infanrix/ https://www.gsk.com/en-gb/products/our-vaccines/infanrix-ipv/ https://www.gsk.com/en-gb/products/our-vaccines/kinrix/ https://www.gsk.com/en-gb/products/our-vaccines/quinvaxem/ https://www.gsk.com/en-gb/products/our-vaccines/menhibrix/ https://www.gsk.com/en-gb/products/our-vaccines/menjugate/ https://www.gsk.com/en-gb/products/our-vaccines/menitorix/ https://www.gsk.com/en-gb/products/our-vaccines/menveo/ https://www.gsk.com/en-gb/products/our-vaccines/pandemrix/ https://www.gsk.com/en-gb/products/our-vaccines/pediarix/ https://www.gsk.com/en-gb/products/our-vaccines/priorix/ https://www.gsk.com/en-gb/products/our-vaccines/priorix-tetra/ https://www.gsk.com/en-gb/products/our-vaccines/rabipur/ https://www.gsk.com/en-gb/products/our-vaccines/rotarix/ https://www.gsk.com/en-gb/products/our-vaccines/synflorix/ https://www.gsk.com/en-gb/products/our-vaccines/twinrix/ https://www.gsk.com/en-gb/products/our-vaccines/typherix/ https://www.gsk.com/en-gb/products/our-vaccines/varilrix/ https://www.gsk.com/en-gb/products/our-vaccines/shingrix/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/oral-health/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/respiratory/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/pain-relief/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/nutrition-and-digestive-health/ https://www.gsk.com/en-gb/products/our-consumer-healthcare-products/skin-health/ https://www.gsk.com/en-gb/products/viiv-healthcare/ https://www.gsk.com/en-gb/products/stiefel-dermatology/ https://www.gsk.com/en-gb/careers/ https://www.gsk.com/en-gb/careers/search-jobs/ https://www.gsk.com/en-gb/careers/covid-19/ https://www.gsk.com/en-gb/careers/experienced-professionals/ https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/ https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/ https://www.gsk.com/en-gb/careers/experienced-professionals/manufacturing-and-supply/ https://www.gsk.com/en-gb/careers/experienced-professionals/marketing-and-communications/ https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/ https://www.gsk.com/en-gb/careers/experienced-professionals/sales/ https://www.gsk.com/en-gb/careers/physicians/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/school-students-what-next/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/apprentice-programmes/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/work-experience-placements-and-internships/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/future-leaders-graduate-programme/ https://www.gsk.com/en-gb/careers/apprentices-students-and-graduates/direct-entry/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/esprit-commercial-pharmaceuticals/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/esprit-commercial-consumer-healthcare/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/esprit-finance/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/mba-internships/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/rd-esprit-programme/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/postdoctoral-rd/ https://www.gsk.com/en-gb/careers/postgraduate-opportunities/postdoctoral-immunology-catalyst/ https://www.gsk.com/en-gb/careers/meet-our-people/ https://www.gsk.com/en-gb/careers/culture-and-values/ https://www.gsk.com/en-gb/careers/career-benefits/ https://www.gsk.com/en-gb/careers/tips-for-applying/ https://www.gsk.com/en-gb/careers/warning-against-fraudulent-internet-recruitment-activities/ https://www.gsk.com/en-gb/investors/ https://www.gsk.com/en-gb/investors/about-gsk/ https://www.gsk.com/en-gb/investors/shareholder-information/ https://www.gsk.com/en-gb/investors/shareholder-information/dividend-calculator-gbp/ https://www.gsk.com/en-gb/investors/shareholder-information/dividend-calculator-usd/ https://www.gsk.com/en-gb/investors/shareholder-information/dividend-calendar/ https://www.gsk.com/en-gb/investors/shareholder-information/manage-your-shares/ https://www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/ https://www.gsk.com/en-gb/investors/shareholder-information/general-meeting/ https://www.gsk.com/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/ https://www.gsk.com/en-gb/investors/shareholder-information/asset-reunification-prosearch/ https://www.gsk.com/en-gb/investors/shareholder-information/faqs/ https://www.gsk.com/en-gb/investors/shareholder-information/share-scam-alert/ https://www.gsk.com/en-gb/investors/shareholder-information/annual-governance-meeting/ https://www.gsk.com/en-gb/investors/shareholder-information/shareholder-privacy-notice/ https://www.gsk.com/en-gb/investors/quarterly-results/ https://www.gsk.com/en-gb/investors/quarterly-results/2016-full-year-and-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2016-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2016-second-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2016-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2015-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2015-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2015-second-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2015-first-quarter-and-prospects-for-newly-shaped-group/ https://www.gsk.com/en-gb/investors/quarterly-results/2014-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2014-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2014-second-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2014-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2013-fourth-quarter-released-05-february-2014/ https://www.gsk.com/en-gb/investors/quarterly-results/2013-third-quarter-released-23-october-2013/ https://www.gsk.com/en-gb/investors/quarterly-results/2013-second-quarter-released-24-july-2013/ https://www.gsk.com/en-gb/investors/quarterly-results/2013-first-quarter-released-24-april-2013/ https://www.gsk.com/en-gb/investors/quarterly-results/2012-fourth-quarter-released-06-february-2013/ https://www.gsk.com/en-gb/investors/quarterly-results/2012-third-quarter-released-31-october-2012/ https://www.gsk.com/en-gb/investors/quarterly-results/2012-second-quarter-released-25-july-2012/ https://www.gsk.com/en-gb/investors/quarterly-results/2012-first-quarter-released-25-april-2012/ https://www.gsk.com/en-gb/investors/quarterly-results/2011-fourth-quarter-released-07-february-2012/ https://www.gsk.com/en-gb/investors/quarterly-results/2011-third-quarter-released-26-october-2011/ https://www.gsk.com/en-gb/investors/quarterly-results/2011-second-quarter-released-26-july-2011/ https://www.gsk.com/en-gb/investors/quarterly-results/2011-first-quarter-released-27-april-2011/ https://www.gsk.com/en-gb/investors/quarterly-results/2010-fourth-quarter-released-03-february-2011/ https://www.gsk.com/en-gb/investors/quarterly-results/2010-third-quarter-released-21-october-2010/ https://www.gsk.com/en-gb/investors/quarterly-results/2010-second-quarter-released-21-july-2010/ https://www.gsk.com/en-gb/investors/quarterly-results/2010-first-quarter-released-28-april-2010/ https://www.gsk.com/en-gb/investors/quarterly-results/2017-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2017-second-quarter-and-investor-event/ https://www.gsk.com/en-gb/investors/quarterly-results/2017-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2017-full-year-and-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2018-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2018-second-quarter-and-rd-update/ https://www.gsk.com/en-gb/investors/quarterly-results/2018-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2018-full-year-and-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2019-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2019-second-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2019-third-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2019-full-year-and-fourth-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2020-first-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2020-second-quarter/ https://www.gsk.com/en-gb/investors/quarterly-results/2020-third-quarter/ https://www.gsk.com/en-gb/investors/corporate-reporting/ https://www.gsk.com/en-gb/investors/corporate-reporting/annual-report-2019/ https://www.gsk.com/en-gb/investors/corporate-reporting/corporate-reporting-archive/ https://www.gsk.com/en-gb/investors/share-price-analysis/ https://www.gsk.com/en-gb/investors/share-price-analysis/gsk-share-price/ https://www.gsk.com/en-gb/investors/share-price-analysis/share-price-calculator-gbp/ https://www.gsk.com/en-gb/investors/share-price-analysis/share-price-calculator-usd/ https://www.gsk.com/en-gb/investors/financial-calendar/ https://www.gsk.com/en-gb/investors/analyst-consensus/ https://www.gsk.com/en-gb/investors/debt-investors/ https://www.gsk.com/en-gb/investors/stock-exchange-announcements/ https://www.gsk.com/en-gb/investors/stock-exchange-announcements/london-rns/ https://www.gsk.com/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/ https://www.gsk.com/en-gb/investors/stock-exchange-announcements/new-york-sec/ https://www.gsk.com/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/ https://www.gsk.com/en-gb/investors/speeches-presentations/ https://www.gsk.com/en-gb/investors/speeches-presentations/35th-annual-jp-morgan-healthcare-conference-san-francisco-usa/ https://www.gsk.com/en-gb/investors/speeches-presentations/meet-the-vaccines-management/ https://www.gsk.com/en-gb/investors/speeches-presentations/hiv-and-viiv-healthcare-presentation-to-goldman-sachs/ https://www.gsk.com/en-gb/investors/speeches-presentations/meet-the-respiratory-management-event/ https://www.gsk.com/en-gb/investors/speeches-presentations/goldman-sachs-37th-annual-global-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-healthcare-bus-tour-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/leerink-partners-5th-annual-global-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/34th-annual-jp-morgan-healthcare-conference-san-francisco-usa/ https://www.gsk.com/en-gb/investors/speeches-presentations/david-redfern/ https://www.gsk.com/en-gb/investors/speeches-presentations/rd-event/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-event/ https://www.gsk.com/en-gb/investors/speeches-presentations/33rd-annual-jp-morgan-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/bank-of-america-merrill-lynch-global-healthcare-conference-london-uk/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-event-at-ers-2014-munich/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-global-healthcare-conference-new-york-usa/ https://www.gsk.com/en-gb/investors/speeches-presentations/32nd-annual-jp-morgan-healthcare-conference-san-francisco-usa/ https://www.gsk.com/en-gb/investors/speeches-presentations/leerink-swann-polarxpress-philadelphia/ https://www.gsk.com/en-gb/investors/speeches-presentations/north-carolina-ceo-forum/ https://www.gsk.com/en-gb/investors/speeches-presentations/goldman-sachs-34th-annual-global-healthcare-conference-california-usa/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-event-at-ats-2013-philadelphia/ https://www.gsk.com/en-gb/investors/speeches-presentations/leerink-swann-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/late-stage-pipeline-review-patrick-vallance/ https://www.gsk.com/en-gb/investors/speeches-presentations/late-stage-pipeline-review-sir-andrew-witty-dr-moncef-slaoui-and-dr-patrick-vallance/ https://www.gsk.com/en-gb/investors/speeches-presentations/annual-pharmaceutical-regulatory-and-compliance-congress/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-meeting-at-esmo-vienna/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-meeting-at-iac-washington/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-meeting-at-ada-philadelphia/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-meeting-at-asco-chicago/ https://www.gsk.com/en-gb/investors/speeches-presentations/world-affairs-council-philadelphia/ https://www.gsk.com/en-gb/investors/speeches-presentations/rd-seminar/ https://www.gsk.com/en-gb/investors/speeches-presentations/pharmehr-summit-philadelphia/ https://www.gsk.com/en-gb/investors/speeches-presentations/annual-jp-morgan-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/core-earnings-reporting/ https://www.gsk.com/en-gb/investors/speeches-presentations/credit-suisse-healthcare-conference-hong-kong/ https://www.gsk.com/en-gb/investors/speeches-presentations/bernstein-conference-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-s-seminar-in-london-on-vaccines-in-emerging-markets/ https://www.gsk.com/en-gb/investors/speeches-presentations/andrew-witty-presents-to-the-us-state-department/ https://www.gsk.com/en-gb/investors/speeches-presentations/presentation-to-investors/ https://www.gsk.com/en-gb/investors/speeches-presentations/cowen-and-company-31st-annual-health-care-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/ced-biotechlife-science-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/the-economist-pharma-summit/ https://www.gsk.com/en-gb/investors/speeches-presentations/cbi-8th-annual-pharmaceutical-compliance-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/jp-morgan-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/ceo-andrew-witty-discusses-rd-and-drug-discovery-on-bbc-radio-4/ https://www.gsk.com/en-gb/investors/speeches-presentations/eddie-gray-president-gsk-pharma-europe-speaks-at-ft-pharmaceutical-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/clsa-china-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/ceo-andrew-witty-featured-in-the-world-in-2011/ https://www.gsk.com/en-gb/investors/speeches-presentations/mind-the-medicine-gap/ https://www.gsk.com/en-gb/investors/speeches-presentations/credit-suisse-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/credit-suisse-healthcare-conference-phoenix-az/ https://www.gsk.com/en-gb/investors/speeches-presentations/sanford-c-bernstein-pan-european-strategic-decisions-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/bank-of-americamerrill-lynch-global-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-meeting-with-john-clarke-president-worldwide-consumer-healthcare/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-visit-to-gsk-biologicals-wavre-belgium/ https://www.gsk.com/en-gb/investors/speeches-presentations/goldman-sachs-thirty-first-annual-health-care-conference-in-california/ https://www.gsk.com/en-gb/investors/speeches-presentations/slides-presented-at-investor-meetings-in-june/ https://www.gsk.com/en-gb/investors/speeches-presentations/2010-citi-investment-research-global-health-care-conference-in-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/jp-morgan-28th-annual-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-event-at-croi-2017-seattle/ https://www.gsk.com/en-gb/investors/speeches-presentations/cowen-37th-annual-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-event-london-2017/ https://www.gsk.com/en-gb/investors/speeches-presentations/evercore-conference-boston/ https://www.gsk.com/en-gb/investors/speeches-presentations/consumer-healthcare-investor-event/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-global-healthcare-conference-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/gsk-oncology-investor-analyst-update/ https://www.gsk.com/en-gb/investors/speeches-presentations/36th-annual-jp-morgan-healthcare-conference-san-francisco-us/ https://www.gsk.com/en-gb/investors/speeches-presentations/consumer-healthcare-update-london/ https://www.gsk.com/en-gb/investors/speeches-presentations/jefferies-2018-healthcare-conference-new-york-city/ https://www.gsk.com/en-gb/investors/speeches-presentations/goldman-sachs-39th-annual-healthcare-conference-california/ https://www.gsk.com/en-gb/investors/speeches-presentations/gemini-results-of-hiv-2-drug-regimen-investor-analyst-update/ https://www.gsk.com/en-gb/investors/speeches-presentations/bank-of-america-merrill-lynch-global-healthcare-conference-london/ https://www.gsk.com/en-gb/investors/speeches-presentations/consumer-healthcare-investor-event-new-jersey/ https://www.gsk.com/en-gb/investors/speeches-presentations/cecp-ceo-investor-forum/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-and-analyst-call-on-gsk-165-agm-csf-data-presented-at-acr/ https://www.gsk.com/en-gb/investors/speeches-presentations/evercore-isi-healthconx-conference-boston/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-2018-global-healthcare-conference-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/analyst-call-on-agreement-to-acquire-tesaro/ https://www.gsk.com/en-gb/investors/speeches-presentations/viiv-meet-the-management-london/ https://www.gsk.com/en-gb/investors/speeches-presentations/analyst-call-on-formation-of-new-consumer-healthcare-jv/ https://www.gsk.com/en-gb/investors/speeches-presentations/37th-annual-jp-morgan-healthcare-conference-san-francisco/ https://www.gsk.com/en-gb/investors/speeches-presentations/guggenheim-healthcare-talks-idea-forum-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/svb-leerink-global-healthcare-conference-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/cowen-co-39th-annual-health-care-conference-boston/ https://www.gsk.com/en-gb/investors/speeches-presentations/viiv-healthcare-analyst-call/ https://www.gsk.com/en-gb/investors/speeches-presentations/jefferies-2019-healthcare-conference-new-york/ https://www.gsk.com/en-gb/investors/speeches-presentations/goldman-sachs-40th-annual-global-healthcare-conference-california/ https://www.gsk.com/en-gb/investors/speeches-presentations/bernstein-consumer-healthcare-nutrition-seminar-london/ https://www.gsk.com/en-gb/investors/speeches-presentations/gsk-vaccines-investor-event/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-and-analyst-call-from-esmo-2019/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-and-analyst-call-from-dreamm-2-data/ https://www.gsk.com/en-gb/investors/speeches-presentations/38th-annual-jp-morgan-healthcare-conference-san-francisco/ https://www.gsk.com/en-gb/investors/speeches-presentations/fireside-chat-at-the-guggenheim-healthcare-talks-idea-forum/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-and-analyst-call-to-discuss-hiv-prevention-treatment-network-083-study/ https://www.gsk.com/en-gb/investors/speeches-presentations/citi-15th-annual-biopharma-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/bofa-global-healthcare-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/investor-and-analyst-call-to-discuss-rsv-vaccines-data/ https://www.gsk.com/en-gb/investors/speeches-presentations/evercore-isi-healthconx-conference/ https://www.gsk.com/en-gb/investors/speeches-presentations/morgan-stanley-esg-insights-conference/ https://www.gsk.com/en-gb/investors/agreement-to-acquire-tesaro/ https://www.gsk.com/en-gb/investors/consumer-healthcare-joint-venture/ https://www.gsk.com/en-gb/investors/investors-contact-details/ https://www.gsk.com/en-gb/media/ https://www.gsk.com/en-gb/media/press-releases/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/ https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-closure-of-agreement-to-divest-non-core-assets-to-aspen/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-of-once-daily-closed-triple-combination-therapy-ffumecvi-in-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-board-changes/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-belimumab-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-opens-new-global-vaccines-rd-center-in-rockville-md-usa/ https://www.gsk.com/en-gb/media/press-releases/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him/ https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-10025-mcg-gains-approval-in-japan-for-use-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-files-eu-regulatory-submission-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles-follows-regulatory-submissions-in-us-and-canada/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-programme-with-daprodustat-for-anaemia-associated-with-chronic-kidney-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-lll-study-of-mepolizumab-meets-co-primary-endpoints-and-all-secondary-endpoints-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/ https://www.gsk.com/en-gb/media/press-releases/gsk-files-regulatory-submission-in-us-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-data-from-phase-iii-studies-of-sirukumab-in-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-benlysta-belimumab-shows-sustained-benefits-in-patients-with-sle/ https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2016/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-in-fourth-consecutive-pivotal-trial-of-benlysta-belimumab-in-sle/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-new-york-times-article-on-china/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-shingles-candidate-vaccine-at-idweek-scientific-conference/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2016/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles/ https://www.gsk.com/en-gb/media/press-releases/new-data-published-for-gsk-s-nucala-investigating-hospitalisation-reduction-in-severe-asthma-patients-with-an-eosinophilic-phenotype/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-brian-mcnamara-as-ceo-of-gsk-consumer-healthcare/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-sale-of-remaining-aspen-shares/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-intention-to-sell-remaining-holding-in-aspen/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-subcutaneous-formulation-of-benlysta-belimumab-for-patients-with-systemic-lupus-disease/ https://www.gsk.com/en-gb/media/press-releases/emma-walmsley-to-succeed-andrew-witty-as-chief-executive-officer-of-glaxosmithkline/ https://www.gsk.com/en-gb/media/press-releases/gsk-sets-out-further-steps-to-address-emerging-global-health-security-challenges/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-shows-high-efficacy-against-shingles-and-its-complications-in-adults-aged-70-years-and-over-in-phase-iii-study-published-in-nejm/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-divests-non-core-assets-to-aspen/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-results-from-phase-iii-fulfil-study-of-closed-triple-combination-therapy-ffumecvi-versus-symbicort-turbohaler-in-copd-at-ers-international-congress/ https://www.gsk.com/en-gb/media/press-releases/real-world-data-shows-83-percent-effectiveness-for-bexsero-in-infants-in-first-year-of-uk-national-meningitis-b-immunisation-programme/ https://www.gsk.com/en-gb/media/press-releases/gsk-announce-positive-results-from-the-copd-salford-lung-study-published-in-the-nejm-and-presented-at-european-respiratory-congress/ https://www.gsk.com/en-gb/media/press-releases/nejm-publishes-results-of-gsk-s-long-term-laba-safety-study-of-advair-diskus-in-children-aged-4-11-years-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-continued-commitment-to-innovative-respiratory-research-demonstrated-in-european-respiratory-society-congress-data-presentations/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-verily-to-establish-galvani-bioelectronics-a-new-company-dedicated-to-the-development-of-bioelectronic-medicines/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2016-and-half-yearly-financial-report-for-the-half-year-2016/ https://www.gsk.com/en-gb/media/press-releases/gsk-in-licenses-anti-il-33r-monoclonal-antibody-for-severe-asthma-from-janssen/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-significant-new-investment-in-uk-manufacturing-network/ https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-call-for-developing-country-innovations-to-enter-1-million-award/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-i-oncology-study-with-its-icos-agonist-antibody/ https://www.gsk.com/en-gb/media/press-releases/fulfil-study-shows-superiority-of-closed-triple-combination-therapy-ffumecvi-versus-symbicort-turbohaler-in-improving-lung-function-and-health-related-quality-of-life-in-copd-patients/ https://www.gsk.com/en-gb/media/press-releases/executive-director-change/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-of-sirukumab-meets-both-co-primary-endpoints-in-patients-with-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/new-phase-iii-data-shows-greater-treatment-response-with-gsk-s-benlysta-belimumab-vs-placebo-in-patients-with-highly-active-sle/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-us-filing-plans-for-closed-triple-combination-therapy-ffumecvi-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/board-and-committee-changes/ https://www.gsk.com/en-gb/media/press-releases/strimvelistm-receives-european-marketing-authorisation-to-treat-very-rare-disease-ada-scid/ https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-publication-of-pivotal-safety-and-efficacy-of-gene-therapy-for-children-with-ada-scid/ https://www.gsk.com/en-gb/media/press-releases/salford-lung-study-results-show-copd-patients-treated-with-relvar-ellipta-achieve-superior-reduction-in-exacerbations-compared-with-usual-care/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-from-breo-ellipta-summit-study-in-patients-with-copd-at-ats-conference/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-efficacy-data-for-anoro-ellipta-in-copd-patients-who-remained-symptomatic-on-tiotropium/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-bexsero-achieves-primary-and-secondary-endpoints-with-reduced-3-dose-schedule-2plus1-in-safety-and-immunogenicity-study-in-infants-and-children/ https://www.gsk.com/en-gb/media/press-releases/european-agency-endorses-antiseptic-gel-developed-through-gsk-and-save-the-children-partnership-for-newborn-umbilical-cord-infections-in-developing-countries/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2016/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-a-phase-ii-study-to-evaluate-an-anti-gm-csf-antibody-for-inflammatory-hand-osteoarthritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-opens-new-state-of-the-art-respiratory-manufacturing-facility-in-ware-uk/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-strimvelis-the-first-gene-therapy-to-treat-very-rare-disease-ada-scid/ https://www.gsk.com/en-gb/media/press-releases/gsk-expands-graduated-approach-to-patents-and-intellectual-property-to-widen-access-to-medicines-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-for-nucala-mepolizumab-in-japan/ https://www.gsk.com/en-gb/media/press-releases/sir-andrew-witty-to-retire-from-gsk-in-march-2017/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-the-company-directorate-changes/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-children-aged-4-11-years-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-miltenyi-biotec-establish-cell-and-gene-therapy-collaboration/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-aaaai-on-efficacy-of-nucala-mepolizumab-in-severe-asthma-patients-stratified-by-eosinophil-levels/ https://www.gsk.com/en-gb/media/press-releases/nejm-publishes-results-of-gsk-s-long-term-laba-safety-study-of-advair-diskus-in-adults-and-adolescents-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-on-the-long-term-efficacy-safety-of-nucala-for-the-treatment-of-severe-asthma-with-an-eosinophilic-phenotype/ https://www.gsk.com/en-gb/media/press-releases/gsk-names-winners-of-2015-discovery-fast-track-challenge/ https://www.gsk.com/en-gb/media/press-releases/new-long-term-organ-damage-analysis-published-for-gsk-s-benlysta-belimumab/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/ https://www.gsk.com/en-gb/media/press-releases/four-inspiring-innovations-which-help-reduce-child-deaths-in-developing-countries-share-1-million-prize-from-gsk-and-save-the-children/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-completes-transactions-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2015/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-expand-strategic-immunotherapy-collaboration/ https://www.gsk.com/en-gb/media/press-releases/update-on-gsk-s-response-to-the-zika-virus-disease-outbreak/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-pneumococcal-vaccine-pricing/ https://www.gsk.com/en-gb/media/press-releases/global-pharmaceutical-industry-calls-on-governments-to-work-with-them-to-beat-the-rising-threat-of-drug-resistance/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection/ https://www.gsk.com/en-gb/media/press-releases/gsk-confronts-copd-to-deliver-new-insights-from-across-the-globe-to-promote-improved-management-of-chronic-lung-disease/ https://www.gsk.com/en-gb/media/press-releases/major-milestone-for-gsknih-candidate-ebola-vaccine-as-first-doses-shipped-to-liberia-for-use-in-phase-iii-clinical-trial/ https://www.gsk.com/en-gb/media/press-releases/gsk-extends-its-price-freeze-commitment-to-ten-years-for-countries-graduating-from-gavi-support/ https://www.gsk.com/en-gb/media/press-releases/board-committee-change/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-three-part-transaction-with-novartis/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-oxford-university-phase-i-trial-results-of-an-ebola-candidate-vaccine/ https://www.gsk.com/en-gb/media/press-releases/four-initiatives-from-across-africa-win-share-of-global-us-1-million-healthcare-innovation-award/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2014/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-overall-survival-results-from-phase-iii-combi-d-study-of-dabrafenib-tafinlar-and-trametinib-mekinist-combination/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-start-of-phase-iii-lung-function-study-with-closed-triple-combination-treatment-ffumecvi-for-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-strengthens-early-stage-vaccine-pipeline-with-acquisition-of-glycovaxyn-ag/ https://www.gsk.com/en-gb/media/press-releases/update-on-three-part-transaction-with-novartis/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-changes-to-its-board/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/ https://www.gsk.com/en-gb/media/press-releases/gsk-transaction-launch/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-new-commitment-to-asia/ https://www.gsk.com/en-gb/media/press-releases/gsk-transaction/ https://www.gsk.com/en-gb/media/press-releases/gsk-becomes-partner-in-new-global-fund-to-accelerate-dementia-research/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-to-evaluate-retosiban-for-spontaneous-preterm-labour/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-outcome-of-us-fda-advisory-committee-on-breo-ellipta-in-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-2015-discovery-fast-track-challenge-seeks-early-drug-discovery-partnerships-with-academics-in-europe-canada-and-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-encruse-ellipta-in-japan-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-meningitis-vaccination-in-the-uk/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-global-vaccines-rd-centre-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-has-demonstrated-efficacy-over-3-4-years-of-follow-up/ https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-for-the-prevention-of-shingles-demonstrates-overall-efficacy-of-972-which-does-not-diminish-in-the-age-groups-studied/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2015/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-and-committee-changes/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-unc-chapel-hill-announce-novel-partnership-to-accelerate-search-for-hiv-cure/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-latest-report-from-the-o-neill-review-on-antibiotic-resistance/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-eclipse-study-shows-association-between-improving-health-status-and-reduced-morbidity-and-mortality-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-ats-on-the-role-of-blood-eosinophil-levels-as-a-potential-biomarker-in-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-japan-regulatory-application-for-mepolizumab-in-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-training-of-frontline-health-workers-across-ghana-kenya-and-nigeria/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-outcome-of-us-fda-advisory-committee-recommending-approval-of-mepolizumab-for-the-treatment-of-adults-with-severe-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-create-independent-research-institute-with-goal-of-radically-changing-and-improving-medicines-development/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-divestment-of-nimenrix-and-mencevax/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-the-francis-crick-institute-join-forces-in-collaboration-to-forge-new-scientific-discoveries/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-2015-call-for-developing-country-healthcare-innovations-to-reduce-child-deaths/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-malaria-candidate-vaccine-mosquirix-rts-s-receives-positive-opinion-from-european-regulators-for-the-prevention-of-malaria-in-young-children-in-sub-saharan-africa/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2015/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-ofatumumab-for-auto-immune-indications-to-novartis-for-up-to-1-billion-plus-royalties/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-phase-3b4-study-of-ambrisentan-and-tadalafil-as-first-line-combination-treatment-in-patients-with-pulmonary-arterial-hypertension/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-build-of-its-largest-indian-tablet-manufacturing-pharmaceutical-factory-in-vemgal-karnataka/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-results-from-the-summit-copd-cv-survival-study/ https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvar-ellipta-for-copd-in-japan/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-novel-anti-il5-biological-nucala-mepolizumab-for-the-treatment-of-patients-with-severe-refractory-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-post-hoc-analysis-of-anoro-ellipta-data-assessing-markers-of-copd-deterioration-compared-to-tiotropium-or-placebo-using-a-novel-composite-endpoint/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-chlorhexidine-gel-for-the-prevention-of-umbilical-cord-infections-in-newborn-babies/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-new-data-comparing-incruse-ellipta-to-tiotropium-and-glycopyrronium-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension/ https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-latitude-timi-60-losmapimod-cardiovascular-study/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-demonstrates-90-efficacy-against-shingles-in-people-70-years-of-age-and-over/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2015/ https://www.gsk.com/en-gb/media/press-releases/gsk-profiles-innovative-rd-portfolio-to-investors/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-bliss-sc-study-of-benlysta-belimumab-administered-subcutaneously-in-patients-with-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-to-expand-indication-for-volibris-in-treatment-of-pulmonary-arterial-hypertension/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries/ https://www.gsk.com/en-gb/media/press-releases/comic-relief-and-gsk-form-five-year-partnership-to-fight-malaria-and-strengthen-health-systems/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-top-line-results-from-sirukumab-phase-iii-programme-supporting-regulatory-filings-for-rheumatoid-arthritis-in-2016/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/ https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-dr-jesse-goodman-to-the-board-as-a-non-executive-director/ https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidinium-vilanterol-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidiniumvilanterol-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-umeclidiniumvilanterol-gains-approval-in-japan-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-flonase-allergy-relief-for-sale-over-the-counter-in-the-united-states/ https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-full-ownership-of-its-indonesian-consumer-healthcare-business/ https://www.gsk.com/en-gb/media/press-releases/gsk-adds-detailed-clinical-trial-data-to-multi-sponsor-request-system-as-part-of-continued-commitment-to-data-transparency/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-interim-result-for-phase-iii-study-of-ofatumumab-as-maintenance-therapy-for-relapsed-cll/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-top-line-results-from-a-phase-iii-study-of-ofatumumab-versus-physicians-choice-for-bulky-fludarabine-refractory-cll/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-eu-authorisation-for-arzerra/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra-ofatumumab/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-start-of-phase-iii-programme-of-tafenoquine-for-plasmodium-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-offer-1-million-award-for-healthcare-innovations-in-developing-countries-that-reduce-child-deaths/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initiation-of-phase-iii-programme-with-fixed-dose-triple-combination-treatment-ffumecvi-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-phase-iii-study-of-fluticasone-furoatevilanterol-in-copd-commenced-to-support-potential-future-filing-in-japan/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-data-from-two-studies-evaluating-the-efficacy-and-safety-of-incruse-ellipta-when-added-to-relvar-breo-ellipta-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-studies-comparing-anoro-ellipta-with-seretide-diskus-and-advair-diskus-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-submission-to-us-regulatory-authorities-for-fluticasone-furoatevilanterol-in-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-in-canada-for-incruse-ellipta-umeclidinium-as-a-treatment-for-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rts-s/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-results-for-phase-iii-study-of-the-combination-of-tafinlar-dabrafenib-and-mekinist-trametinib-in-metastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-commitment-to-improve-access-to-vaccines-with-5-year-price-freeze-for-countries-graduating-from-gavi-alliance-support/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-strategic-investments-in-africa-to-increase-access-to-medicines-build-capacity-and-deliver-sustainable-growth/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-altto-results-for-anti-her2-therapy-combination-in-the-adjuvant-breast-cancer-treatment-setting/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-with-darapladib-did-not-meet-primary-endpoint-in-patients-following-an-acute-coronary-syndrome/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-studies-for-mepolizumab-in-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-for-copd-in-japan/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-of-phase-iii-petit2-study-of-eltrombopag-promacta-revolade-in-paediatric-patients-with-chronic-immune-thrombocytopenia/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-cardiovascular-outcomes-study-with-losmapimod-in-patients-with-acute-coronary-syndrome/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-for-mepolizumab-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-lll-study-for-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-submission-to-us-regulatory-authorities-for-promacta-eltrombopag-for-severe-aplastic-anaemia/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-the-start-of-a-phase-iii-study-with-eltrombopag-in-patients-with-myelodysplastic-syndromes/ https://www.gsk.com/en-gb/media/press-releases/gsk-comment-china-investigation/ https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/ https://www.gsk.com/en-gb/media/press-releases/gsk-gains-fda-breakthrough-therapy-designation-for-promacta-revolade-eltrombopag-for-severe-aplastic-anaemia/ https://www.gsk.com/en-gb/media/press-releases/gsk-increases-stake-in-indian-pharmaceuticals-subsidiary-to-75-per-cent-after-open-offer/ https://www.gsk.com/en-gb/media/press-releases/gsk-kicks-off-2014-discovery-fast-track-challenge-for-academic-drug-hunters-in-europe-canada-and-usa/ https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-from-phase-iii-stability-study-of-darapladib-in-patients-with-chronic-coronary-heart-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-once-weekly-tanzeumeperzan-albiglutide-showing-blood-glucose-lowering-up-to-three-years-in-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-at-ats-2014-from-study-evaluating-efficacy-and-safety-of-incruse-ellipta-added-to-advair-diskus-in-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-historical-quarterly-restated-financial-information/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-incruse-umeclidinium-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-mekinist-trametinib-for-patients-with-unresectable-or-metastatic-melanoma-with-a-braf-v600-mutation/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-authorisation-for-once-weekly-type-2-diabetes-treatment-eperzan-albiglutide/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-arnuity-ellipta-fluticasone-furoate-in-the-usa-for-the-treatment-of-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-incruse-umeclidinium-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-mekinist-trametinib-in-metastatic-melanoma-with-a-braf-v600-mutation/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-the-chmp-in-europe-for-once-weekly-eperzantm-albiglutide-for-the-treatment-of-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-for-once-weekly-type-2-diabetes-treatment-tanzeum-albiglutide/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-recent-media-coverage-related-to-our-china-business/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-bbc-panorama-programme/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-media-reports/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-recent-media-coverage-related-to-our-china-business/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-uk-government-initiated-review-of-antibiotic-resistance/ https://www.gsk.com/en-gb/media/press-releases/investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoints-in-magrit-a-phase-iii-non-small-cell-lung-cancer-clinical-trial/ https://www.gsk.com/en-gb/media/press-releases/motherapy-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/ https://www.gsk.com/en-gb/media/press-releases/patient-recruitment-completes-in-landmark-relvar-breo-ellipta-study-to-understand-mortality-and-morbidity-summit-in-copd/ https://www.gsk.com/en-gb/media/press-releases/prosensa-regains-rights-to-drisapersen-from-gsk-and-retains-rights-to-all-other-programmes-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-combined-use-of-mekinist-trametinib-and-tafinlar-dabrafenib-in-europe/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-votrient-pazopanib-as-maintenance-therapy-for-advanced-ovarian-cancer-in-the-eu/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-fourth-quarter-2013/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2014/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2014/ https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/ https://www.gsk.com/en-gb/media/press-releases/serious-fraud-office-investigation/ https://www.gsk.com/en-gb/media/press-releases/tafinlar-receives-fda-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/ https://www.gsk.com/en-gb/media/press-releases/trametinib-mekinist-and-dabrafenib-tafinlar-combination-demonstrated-overall-survival-benefit-compared-to-vemurafenib-phase-iii-braf-v600-mutant-metastatic-melanoma-study-stopped-early/ https://www.gsk.com/en-gb/media/press-releases/triumeq-dolutegravirabacavirlamivudine-single-tablet-regimen-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-collaboration-with-janssen-to-investigate-single-tablet-regimen-for-maintenance-treatment-of-hiv-1/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-approval-for-triumeq-abacavir-dolutegravir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-1-infection/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe/ https://www.gsk.com/en-gb/media/press-releases/where-do-you-start-when-developing-a-new-medicine/ https://www.gsk.com/en-gb/media/press-releases/ebola-vaccine-trials-fast-tracked-by-international-consortium/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-data-presented-at-ers-demonstrate-potential-of-blood-eosinophil-levels-to-help-inform-copd-treatment-decisions/ https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-and-ers-publish-positive-results-from-gsk-phase-iii-studies-of-mepolizumab-in-patients-with-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study/ https://www.gsk.com/en-gb/media/press-releases/gsk-gold-and-the-copd-foundation-announce-formation-of-a-new-external-expert-governance-board-for-the-copd-assessment-test-cat/ https://www.gsk.com/en-gb/media/press-releases/gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases-in-africa/ https://www.gsk.com/en-gb/media/press-releases/gsk-china-investigation-outcome/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-sir-philip-hampton-to-the-board-of-directors/ https://www.gsk.com/en-gb/media/press-releases/international-collaboration-to-develop-inhaled-form-of-oxytocin-to-manage-bleeding-after-childbirth-in-developing-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-overall-survival-results-from-phase-iii-break-3-study-of-tafinlar-dabrafenib-in-patients-with-braf-v600e-mutant-metastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund/ https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-mr-urs-rohner-to-its-board-as-a-non-executive-director/ https://www.gsk.com/en-gb/media/press-releases/stiefel-a-gsk-company-announces-start-of-phase-iii-study-of-subcutaneous-ofatumumab-for-pemphigus-vulgaris/ https://www.gsk.com/en-gb/media/press-releases/data-published-on-anoro-ellipta-demonstrate-improved-lung-function-compared-to-tiotropium/ https://www.gsk.com/en-gb/media/press-releases/gsk-update-on-current-development-status-of-the-gsknih-ebola-vaccine-candidate/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2014/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-mepolizumab-in-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade-1/ https://www.gsk.com/en-gb/media/press-releases/gsk-launches-first-call-for-proposals-for-research-in-to-non-communicable-diseases-in-sub-saharan-africa/ https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2014/ https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-publishes-positive-results-from-combi-v-study-of-trametinib-mekinist-and-dabrafenib-tafinlar-combination/ https://www.gsk.com/en-gb/media/press-releases/publication-of-circular-and-notice-of-general-meeting-relating-to-the-proposed-major-transaction-with-novartis/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-first-phase-1-trial-results-of-a-candidate-ebola-vaccine/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-transaction-with-novartis/ https://www.gsk.com/en-gb/media/press-releases/gsk-names-winners-of-2014-discovery-fast-track-challenge/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-established-products-portfolio/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-extended-indication-for-ambrisentan-volibris-in-pulmonary-arterial-hypertension/ https://www.gsk.com/en-gb/media/press-releases/new-european-consortium-formed-to-help-further-advance-development-of-a-gsknih-ebola-candidate-vaccine/ https://www.gsk.com/en-gb/media/press-releases/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-additional-indication-for-eltrombopag-promacta/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-anoro-umecvi-in-europe/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submission-of-albiglutide-bla-to-the-us-fda-for-the-treatment-of-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-up-to-uk-government-s-public-health-responsibility-deal/ https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-hans-wijers-to-its-board-as-a-non-executive-director/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-biological-e-announce-joint-venture-to-develop-combination-vaccine-for-india-and-other-developing-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-response-to-news-article-in-the-guardian-on-uk-legal-proceedings-related-to-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-starts-phase-iii-study-to-test-combined-brafmek-inhibition-in-patients-with-braf-positive-melanoma-following-surgery/ https://www.gsk.com/en-gb/media/press-releases/gsk-increases-stake-in-its-publicly-listed-consumer-healthcare-subsidiary-in-india-to-725-per-cent/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-support-for-alltrials-campaign-for-clinical-data-transparency/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2012/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-european-submission-for-mek-monotherapy-and-brafmek-combination-therapy-in-metastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-fda-acceptance-of-new-drug-application-nda-submission-in-the-us-for-anoro-elliptatm-for-copd/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-regulatory-submission-for-albiglutide-in-europe/ https://www.gsk.com/en-gb/media/press-releases/young-scientists-challenged-by-gsk-and-mclaren-to-help-drive-science-behind-formula-1/ https://www.gsk.com/en-gb/media/press-releases/500-000-endowment-gift-from-the-glaxosmithkline-foundation-expands-program-to-help-patients-with-cancer-and-their-families-at-the-children-s-hospital-of-philadelphia/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2012-corporate-responsibility-report/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-receives-complete-response-from-fda-for-candidate-pandemic-h5n1-adjuvanted-influenza-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-four-strain-seasonal-influenza-vaccine-granted-marketing-authorisation-in-germany-and-the-uk/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-start-of-phase-iii-study-of-benlysta-belimumab-in-patients-with-vasculitis/ https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-recommends-approval-of-breo-tm-ellipta-tm-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-oft-statement-of-objections/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-anoro-ellipta-umecvi-in-japan/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2013/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-in-european-union/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-impax-pharmaceuticals-terminate-their-collaboration-on-ipx066/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-in-us/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-trametinib-us-pdufa-date-extended-to-3-september-2013/ https://www.gsk.com/en-gb/media/press-releases/funding-boost-for-gsk-s-open-innovation-research-into-diseases-affecting-the-developing-world/ https://www.gsk.com/en-gb/media/press-releases/gsk-gives-update-on-plans-to-share-detailed-clinical-trial-data-as-part-of-its-commitment-to-transparency/ https://www.gsk.com/en-gb/media/press-releases/gsk-enters-new-commitment-with-the-gavi-alliance-to-supply-cervical-cancer-vaccine-for-girls-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-form-unique-partnership-to-save-the-lives-of-one-million-children/ https://www.gsk.com/en-gb/media/press-releases/breo-ellipta-gains-us-approval-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-awarded-up-to-200-million-by-us-government-to-develop-new-antibiotics/ https://www.gsk.com/en-gb/media/press-releases/grant-to-help-coordinate-campaign-to-train-one-million-community-health-workers-in-sub-saharan-africa/ https://www.gsk.com/en-gb/media/press-releases/gsk-strengthens-vaccines-business-with-acquisition-of-okairos/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-top-line-results-from-pivotal-trial-of-arzerra-ofatumumab-combined-with-chlorambucil-in-previously-untreated-chronic-lymphocytic-leukaemia/ https://www.gsk.com/en-gb/media/press-releases/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-the-first-mek-inhibitor-mekinist-trametinib-tablets-approved-by-fda-as-single-agent-therapies/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-late-stage-clinical-data-for-votrient-pazopanib-following-chemotherapy-in-women-with-advanced-epithelial-ovarian-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-data-for-tykerbtyverb-lapatinib-in-combination-with-chemotherapy-for-advanced-her2-positive-gastric-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-fda-advisory-committee-s-vote-on-availability-of-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-regarding-2010-nature-medicine-study/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-offer-for-its-thrombosis-brands-and-related-manufacturing-site/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-from-five-phase-iii-studies-of-albiglutide-an-investigational-once-weekly-treatment-for-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-1-million-award-to-discover-new-healthcare-innovations-for-reducing-child-deaths/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-s-drisapersen-previously-gsk2402968pro051-to-receive-food-and-drug-administration-breakthrough-therapy-designation/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-receives-positive-chmp-opinions-for-tafinlar-dabrafenib-and-tyverb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-us-submission-for-dabrafenibtrametinib-combination-in-metastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-fluticasone-furoatevilanterol-submission-in-japan/ https://www.gsk.com/en-gb/media/press-releases/gsk-response-to-china-investigation/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-regarding-recent-meeting-with-chinese-authorities/ https://www.gsk.com/en-gb/media/press-releases/update-on-gsk-consumer-nigeria-plc-scheme-of-arrangement/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2013/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/ https://www.gsk.com/en-gb/media/press-releases/gsk-adds-to-its-commitment-to-gavi-alliance-to-help-protect-millions-more-children-against-infectious-diseases/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-albiglutide-us-pdufa-date-extended-by-three-months/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-eu-submission-seeking-additional-indication-for-votrient-as-maintenance-therapy-for-advanced-ovarian-cancer/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-eu-submission-for-cervarix-two-dose-schedule/ https://www.gsk.com/en-gb/media/press-releases/gsk-launches-50-million-venture-capital-fund-to-invest-in-pioneering-bioelectronic-medicines-and-technologies/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-indication-tyverb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-of-vercirnon-in-patients-with-moderate-to-severe-crohn-s-disease-did-not-meet-its-primary-endpoint/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-tafinlar/ https://www.gsk.com/en-gb/media/press-releases/the-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoint-in-phase-iii-melanoma-clinical-trial/ https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-divest-lucozade-and-ribena-for-135-billion/ https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-recommends-approval-in-us-of-umeclidiniumvilanterol-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-naïve-adults-with-hiv-1/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-patent-ruling-reversal-on-lovaza/ https://www.gsk.com/en-gb/media/press-releases/fda-grants-gsk-and-genmab-s-arzerra-ofatumumab-breakthrough-therapy-designation-for-previously-untreated-chronic-lymphocytic-leukaemia/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-priority-review-from-fda-for-dabrafenibtrametinib-combination-in-metastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-a-multi-year-agreement-with-barda-to-supply-the-us-government-with-anthrax-treatment/ https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-asthma-and-copd/ https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-gains-approval-in-japan-for-the-treatment-of-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-prosensa-announce-primary-endpoint-not-met-in-phase-iii-study-of-drisapersen-in-patients-with-duchenne-muscular-dystrophy/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-barclays-form-partnership-to-increase-access-to-healthcare-and-promote-economic-development-in-zambia/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-with-aspen-to-divest-thrombosis-brands-and-related-manufacturing-site-for-07-billion/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-genmab-announce-european-submission-to-regulatory-authorities-for-arzerra-ofatumumab-as-1st-line-treatment-of-chronic-lymphocytic-leukaemia-cll/ https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-reduces-disease-over-18-months-of-follow-up-in-late-stage-study-of-more-than-15-000-infants-and-young-children/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-genmab-announce-submission-to-us-regulatory-authorities-for-arzerra-ofatumumab-as-1st-line-treatment-of-chronic-lymphocytic-leukaemia-cll/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-fluticasone-furoate-monotherapy-for-asthma/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2013/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-create-a-new-centre-of-excellence-for-sustainable-chemistry-in-brazil/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-european-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/synflorix-receives-positive-opinion-from-the-chmp-in-europe-for-additional-pneumonia-indication/ https://www.gsk.com/en-gb/media/press-releases/new-partnership-between-gsk-and-the-bill-melinda-gates-foundation-to-accelerate-research-into-vaccines-for-global-health-needs/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-to-support-cervarix-two-dose-schedule-for-the-prevention-of-cervical-cancer-in-9-14-year-old-girls/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-apprentice-and-graduate-engineering-opportunities-in-the-uk-during-tomorrow-s-engineers-week/ https://www.gsk.com/en-gb/media/press-releases/gsk-names-inaugural-winners-in-unique-competition-for-academic-drug-hunters/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-top-line-results-from-pivotal-phase-iii-study-of-darapladib-in-chronic-coronary-heart-disease/ https://www.gsk.com/en-gb/media/press-releases/five-inspirational-organisations-from-malawi-bangladesh-mali-kenya-and-colombia-recognised-by-gsk-and-save-the-children/ https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-receives-european-marketing-authorisation-for-the-treatment-of-asthma-and-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-announce-revised-fabry-agreement/ https://www.gsk.com/en-gb/media/press-releases/tivicay-dolutegravir-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/h5n1-vaccine-approved-by-the-us-fda-as-pandemic-influenza-preparedness-measure/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-fda-decision-on-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-receives-positive-chmp-opinion-for-cervarix-two-dose-schedule/ https://www.gsk.com/en-gb/media/press-releases/synflorix-receives-european-marketing-authorisation-for-additional-pneumonia-indication/ https://www.gsk.com/en-gb/media/press-releases/gsk-launches-global-consortium-with-six-renowned-cancer-research-centres/ https://www.gsk.com/en-gb/media/press-releases/update-regarding-2010-nature-medicine-study/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-pivotal-phase-iii-study-for-fluticasone-furoatevilanterol-in-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-200-million-investment-in-uk-advanced-manufacturing-and-science/ https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-voluntary-open-offer-to-increase-stake-in-its-pharmaceuticals-subsidiary-in-india/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-its-global-sales-and-marketing-practices-to-further-ensure-patient-interests-come-first/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-priority-review-from-fda-for-arzerra-ofatumumab-as-1st-line-treatment-for-chronic-lymphocytic-leukaemia-cll/ https://www.gsk.com/en-gb/media/press-releases/update-on-patent-ruling-on-viiv-healthcares-epzicom-and-trizivir/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-1-million-innovation-prize-for-bioelectronics-research/ https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-approved-as-first-once-daily-dual-bronchodilator-for-the-treatment-of-copd-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-fda-breakthrough-therapy-designation-for-tafenoquine-for-plasmodium-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-thrombosis-brands-and-related-manufacturing-site-to-aspen/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-lucozade-and-ribena-to-suntory/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-positive-opinion-in-europe-from-the-chmp-for-nimenrixreg/ https://www.gsk.com/en-gb/media/press-releases/eu-and-us-regulatory-update-tykerbtyverb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/gsk-results-announcement-for-q4-and-full-year-2011/ https://www.gsk.com/en-gb/media/press-releases/gsk-joins-new-global-partnership-to-help-defeat-ten-neglected-tropical-diseases-by-2020/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-the-board/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-the-recent-court-ruling-on-the-compas-study-in-mendoza-argentina/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initial-outcomes-from-pivotal-phase-iii-studies-for-once-daily-relovair-star-in-copd-and-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-daiichi-sankyo-vaccines-joint-venture-to-become-largest-vaccines-company-in-japan/ https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-for-two-influenza-vaccines/ https://www.gsk.com/en-gb/media/press-releases/gsk-reinforces-commitment-to-youth-training-with-launch-of-new-uk-apprenticeship-programme/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-provides-further-update-on-divestment-of-non-core-over-the-counter-otc-brands/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-vote-from-fda-panel-for-pazopanib-in-certain-advanced-soft-tissue-sarcomas/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-increase-its-ownership-in-theravance/ https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-significant-investments-in-uk-manufacturing-ulverston-in-cumbria-selected-as-site-of-new-biopharmaceutical-factory/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-completion-of-the-relovair-star-registrational-programme-and-topline-results-from-relovair-vs-advair-phase-iii-studies-in-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-further-data-from-phase-lll-studies-of-albiglutide-in-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-corporate-responsibility-commitments-in-2011-report/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-yale-university-establish-drug-discovery-collaboration-to-design-potential-new-class-of-medicines/ https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-two-non-executive-directors-to-its-board/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-to-divest-non-core-over-the-counter-otc-brands-in-international-markets-for-164-million/ https://www.gsk.com/en-gb/media/press-releases/james-shannon-named-glaxosmithkline-chief-medical-officer/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2012/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-commence-tender-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-university-of-nottingham-collaborate-to-create-centre-of-excellence-for-sustainable-chemistry/ https://www.gsk.com/en-gb/media/press-releases/children-in-ghana-to-be-vaccinated-against-diarrhoeal-disease-with-the-introduction-of-gsk-s-rotarix-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-commences-tender-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ https://www.gsk.com/en-gb/media/press-releases/stiefel-receives-us-fda-approval-of-fabior-foam-01/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-bbc-panorama-broadcast-the-truth-about-tax/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-fully-acquire-cellzome-for-61-million/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-transaction-to-increase-its-ownership-in-theravance/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-tender-offer-to-acquire-human-genome-sciences/ https://www.gsk.com/en-gb/media/press-releases/two-overall-winners-announced-at-prestigious-national-award-ceremony-in-london-s-science-museum/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-votrient-for-treatment-of-patients-with-certain-types-of-advanced-soft-tissue-sarcoma/ https://www.gsk.com/en-gb/media/press-releases/innovative-public-private-collaboration-launches-to-tackle-antibiotic-research/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-european-chmp-for-pazopanib-in-the-treatment-of-patients-with-certain-advanced-soft-tissue-sarcomas/ https://www.gsk.com/en-gb/media/press-releases/gsk-secures-future-of-local-playing-fields-with-fields-in-trust-as-part-of-london-2012-legacy/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-european-authorisation-for-nimenrix-meningococcal-group-a-c-w-135-and-y-conjugate-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-for-combination-of-dabrafenib-gsk2118436-and-trametinib-gsk1120212-in-braf-v600-mutation-positive-metastatic-cutaneous-melanoma/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-confirms-us-district-court-ruling-in-pronova-biopharma-s-favour-on-lovaza-patents/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-expiration-of-hart-scott-rodino-waiting-period-for-tender-offer-for-hgs/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-in-the-eu-us-for-new-indications-for-promacta-revolade/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-epsrc-announce-creation-of-new-chair-in-sustainable-chemistry-at-the-university-of-nottingham/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-xenoport-receive-fda-approval-for-horizant-for-postherpetic-neuralgia/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-concludes-previously-announced-agreement-in-principle-to-resolve-multiple-investigations-with-us-government-and-numerous-states/ https://www.gsk.com/en-gb/media/press-releases/gsk-extends-tender-offer-for-all-outstanding-shares-of-human-genome-sciences/ https://www.gsk.com/en-gb/media/press-releases/gsk-sets-20-july-for-expiration-of-tender-offer-to-acquire-human-genome-sciences/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-52-week-data-from-phase-iii-study-of-once-weekly-albiglutide-in-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-continues-with-tender-offer-to-acquire-all-outstanding-shares-of-human-genome-sciences/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-menhibrix/ https://www.gsk.com/en-gb/media/press-releases/stiefel-signs-worldwide-acquisition-and-license-agreement-for-toctino/ https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-data-from-harmony-8-and-completion-of-clinical-registration-package-for-albiglutide-in-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/us-regulatory-update-tykerb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-celebrates-its-role-in-supporting-the-biggest-anti-doping-operation-in-the-history-of-the-olympic-games/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-human-genome-sciences-for-us-1425-per-share-in-cash/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-amicus-therapeutics-expand-fabry-disease-collaboration/ https://www.gsk.com/en-gb/media/press-releases/innovative-uk-research-project-to-study-the-value-medicines-bring-to-patients-in-the-real-world/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-of-sirukumab-in-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-in-the-eu-and-us-for-dabrafenib-and-trametinib/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-human-genome-sciences/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-to-divest-majority-of-classic-brands-in-australia-for-172m/ https://www.gsk.com/en-gb/media/press-releases/european-commission-grants-marketing-authorisation-for-pazopanib-votrient-in-the-treatment-of-certain-advanced-soft-tissue-sarcoma-subtypes/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2012/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-acquisition-of-79-of-human-genome-sciences-shares-commences-subsequent-offering-period/ https://www.gsk.com/en-gb/media/press-releases/maximuscle-powers-vodafone-mclaren-mercedes-drivers-through-the-2012-formula-1-season/ https://www.gsk.com/en-gb/media/press-releases/gsk-pre-broadcast-statement-on-bbc-panorama-the-truth-about-sports-products-19-july-2012/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submission-for-a-new-indication-for-synflorix-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-five-million-shares-in-response-genetics-for-us-110-per-share-in-cash/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-completion-of-the-phase-iii-programme-for-once-daily-lamalaba-umecvi-in-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-fda-acceptance-of-ffvi-new-drug-application-nda-submission-in-the-us-for-copd/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-changes-to-its-board-and-committees/ https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/ https://www.gsk.com/en-gb/media/press-releases/millions-of-children-in-pakistan-to-be-protected-against-pneumococcal-disease-with-gsk-s-synflorix/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-initiatives-to-advance-openness-and-collaboration-to-help-tackle-global-health-challenges/ https://www.gsk.com/en-gb/media/press-releases/results-from-five-phase-iii-studies-presented-for-gsk-s-two-candidate-quadrivalent-influenza-vaccines/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-four-strain-seasonal-influenza-vaccine-for-use-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-umecvi-lamalaba-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-provides-update-on-divestment-of-non-core-over-the-counter-otc-brands/ https://www.gsk.com/en-gb/media/press-releases/gsk-extends-pneumococcal-vaccine-agreement-with-gavi-alliance/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-initiate-phase-iii-trial-of-belimumab-benlystareg-administered-subcutaneously-in-subjects-with-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-lll-data-for-lapatinib-at-san-antonio-breast-cancer-symposium/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-help-for-heroes-partner-to-support-the-rehabilitation-of-wounded-servicemen-and-women-in-the-uk/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-the-prime-minister-s-speech-on-life-sciences/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-submits-additional-information-for-candidate-meningococcal-and-hib-combination-vaccine/ https://www.gsk.com/en-gb/media/press-releases/reporting-on-a-core-earnings-basis-will-begin-with-effect-from-q1-2012/ https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-gavi-alliance-decision-to-introduce-vaccines-against-cervical-cancer-and-rubella-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-welcomes-innovative-knowledge-sharing-collaboration-to-break-deadlock-in-antibiotic-discovery-and-development/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-initial-data-from-the-first-completed-phase-lll-study-of-albiglutide-in-type-2-diabetes/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-iii-results-for-eltrombopag-in-hepatitis-c-virus-related-thrombocytopenia/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-in-principle-to-resolve-multiple-investigations-with-us-government/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q3-performance-with-underlying-sales-growth-of-6-and-reported-sales-growth-of-3/ https://www.gsk.com/en-gb/media/press-releases/gsk-joins-wipo-research-open-innovation-platform-as-part-of-its-commitment-to-tackling-diseases-of-the-developing-world/ https://www.gsk.com/en-gb/media/press-releases/first-results-from-ongoing-phase-iii-trial-show-malaria-vaccine-candidate-rts-sstar-reduces-the-risk-of-malaria-by-half-in-african-children-aged-5-to-17-months/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-receives-complete-response-letter-from-fda-for-candidate-meningococcal-and-hib-combination-vaccine/ https://www.gsk.com/en-gb/media/press-releases/lucozade-to-help-drive-vodafone-mclaren-mercedes-performance/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-and-mclaren-group-announce-innovative-strategic-partnership/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-commits-1-million-in-cervical-cancer-vaccine-to-new-cooperative-effort-aimed-at-reducing-deaths-from-womens-cancers/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-amicus-therapeutics-commence-second-phase-iii-study-of-amigal-for-fabry-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-gives-update-on-agreement-with-world-health-organization-to-support-de-worming-of-school-age-children-in-endemic-countries/ https://www.gsk.com/en-gb/media/press-releases/lapatinib-clinical-trial-update/ https://www.gsk.com/en-gb/media/press-releases/jens-eckstein-named-president-of-sr-one-gsk-s-venture-healthcare-group/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-shows-sign-of-things-to-come-at-london-2012-olympic-and-paralympic-games/ https://www.gsk.com/en-gb/media/press-releases/gsk-awarded-contract-by-barda-to-support-research-on-potential-novel-antibiotic/ https://www.gsk.com/en-gb/media/press-releases/gsk-takes-minority-stake-in-new-spin-out-autifony-therapeutics/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-impax-announce-positive-topline-results-of-ascend-pd-phase-iii-study-of-ipx066-in-advanced-parkinson-s-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-collaboration-on-assay-development-and-commercialisation-of-enigma-s-ml-platform/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-xenoport-submit-supplemental-new-drug-application-to-fda-for-horizant-in-postherpetic-neuralgia/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-stiefel-a-gsk-company-files-nda-for-tazarotene-foam/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-performance-with-underlying-sales-growthstar-of-5-increased-pipeline-visibility-and-dividend-of-16p-up-7/ https://www.gsk.com/en-gb/media/press-releases/eu-and-us-regulatory-update-votrientreg-pazopanib/ https://www.gsk.com/en-gb/media/press-releases/london-2012-partner-glaxosmithkline-shares-scientific-expertise-with-world-anti-doping-agency-to-help-fight-against-abuse-of-drugs-in-sport/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-new-approval-for-rotarix-and-significant-new-indication-for-lamictalreg-lamotrigine-in-japan/ https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-external-scientists-to-diseases-of-the-developing-world-research-campus/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-university-of-east-anglia-study-examining-health-impacts-of-anticholinergic-medicines-for-over-65s/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-agreements-with-state-attorneys-general-on-former-cidra-manufacturing-facility/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-purchase-shenzhen-neptunus-stake-in-previously-formed-joint-venture-for-influenza-vaccines-in-china/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-valeant-announce-us-fda-approval-of-potiga-ezogabine/ https://www.gsk.com/en-gb/media/press-releases/millions-of-children-in-the-world-s-poorest-countries-could-receive-vaccination-against-rotavirus-diarrhoeal-disease-under-new-offer-made-by-gsk-to-the-gavi-alliance/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-s-pazopanib-improved-progression-free-survival-in-adults-with-certain-soft-tissue-sarcomas/ https://www.gsk.com/en-gb/media/press-releases/gsk-forms-partnership-with-three-leading-ngos-to-address-shortage-of-frontline-healthcare-workers-in-least-developed-countries-ldcs/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-positive-opinion-in-europe-from-the-chmp-for-benlysta-belimumab/ https://www.gsk.com/en-gb/media/press-releases/young-peoples-health-charity-steps-forward-to-claim-top-accolade-and-35-000/ https://www.gsk.com/en-gb/media/press-releases/pharmaceutical-industry-and-university-create-manchester-collaborative-centre-for-inflammation-research/ https://www.gsk.com/en-gb/media/press-releases/gsk-q1-performance-demonstrates-continued-progress-with-delivery-of-underlying-sales-growth-cash-generation-and-pipeline-visibility/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-valeant-respond-to-fda-on-ezogabine/ https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/ https://www.gsk.com/en-gb/media/press-releases/gsk-european-regulatory-update-on-pandemrix/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-tyverbreg-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-non-core-otc-products-to-be-divested/ https://www.gsk.com/en-gb/media/press-releases/unique-research-alliance-expands-collaboration-opportunities-at-state-of-the-art-medical-imaging-centre/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-receive-fda-approval-for-horizant/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-payments-for-research-consulting-and-advising-by-us-healthcare-professionals/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-confirms-pronova-biopharma-reaches-agreement-with-apotex-regarding-lovaza-us-patent-litigation/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2010-corporate-responsibility-report/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-avodart-dutasteride-for-prostate-cancer-risk-reduction/ https://www.gsk.com/en-gb/media/press-releases/gsk-launches-london-2012-initiative-with-king-s-college-london-to-inspire-young-people-into-science-careers/ https://www.gsk.com/en-gb/media/press-releases/gsk-supports-recovery-efforts-to-help-those-affected-by-the-japan-earthquake/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-topline-results-of-phase-lll-study-of-ipx066-in-advanced-parkinson-s-disease/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-tolerx-announce-phase-iii-defend-1-study-of-otelixizumab-in-type-1-diabetes-did-not-meet-its-primary-endpoint/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-approval-of-benlystareg-belimumab-for-the-treatment-of-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-two-non-executive-directors-to-its-board-1/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-nimenrixreg-menacwy-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-outlines-new-plan-to-drive-recruitment-and-attract-graduate-talent-in-the-uk/ https://www.gsk.com/en-gb/media/press-releases/reward-for-charities-bridging-gaps-in-health-care-provision/ https://www.gsk.com/en-gb/media/press-releases/world-s-first-everyday-fluoride-toothpaste-with-novamin-technology-that-can-repair-sensitive-teeth/ https://www.gsk.com/en-gb/media/press-releases/david-redfern-appointed-as-new-chairman-of-viiv-healthcare/ https://www.gsk.com/en-gb/media/press-releases/first-african-country-introduces-gsk-s-pneumococcal-vaccine-through-innovative-financing-mechanism/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-moving-to-new-building-at-philadelphia-navy-yard/ https://www.gsk.com/en-gb/media/press-releases/gsk-revises-us-avandia-label-to-include-new-restrictions-on-use/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-publication-of-bliss-52-phase-lll-study-results-for-benlysta-in-the-lancet/ https://www.gsk.com/en-gb/media/press-releases/gsk-results-announcement-for-the-fourth-quarter/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-the-sale-of-its-entire-shareholding-in-quest-diagnostics/ https://www.gsk.com/en-gb/media/press-releases/update-on-pandemrix-and-interim-finnish-report-on-narcolepsy/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-actelion-discontinue-clinical-development-of-almorexant/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-complete-response-letter-for-avodart-for-prostate-cancer-risk-reduction-supplemental-indication/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-start-of-two-phase-iii-studies-in-advancedmetastatic-melanoma/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-valeant-receive-positive-opinion-in-europe-from-the-chmp-for-trobalt-retigabine/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-prosensa-announce-start-of-phase-iii-study-of-investigational-duchenne-muscular-dystrophy-medication/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-commences-phase-iii-study-of-intravenous-zanamivir-for-hospitalised-patients-with-influenza/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-q4-2010-legal-charge/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-chemocentryx-announce-initiation-of-phase-iii-study-of-gsk-786-formerly-traficet-en-for-the-treatment-of-crohn-s-disease/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-dentsply-international-sign-global-agreement-to-create-a-portfolio-of-co-branded-professional-oral-care-products/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-60-minutes/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-european-regulatory-update-on-pandemrix/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-european-authorisation-for-benlysta-belimumab/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-receive-european-authorisation-for-trobalt-retigabine/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-progression-of-lamalaba-combination-treatment-into-phase-iii-development-for-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-results-of-two-pivotal-phase-iii-studies-for-relovair-in-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-european-regulatory-update-on-pandemrix-1/ https://www.gsk.com/en-gb/media/press-releases/data-published-in-the-lancet-oncology-support-high-efficacy-previously-demonstrated-by-cervarixreg-hpv-16-and-18-vaccine-against-precancerous-cervical-lesions/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-theravance-commence-maba-phase-iib-copd-study/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-impax-pharmaceuticals-enter-global-agreement-to-develop-and-commercialise-a-late-stage-compound-for-parkinson-s-disease/ https://www.gsk.com/en-gb/media/press-releases/andrew-witty-appointed-lead-non-executive-board-member-for-the-department-for-business-innovation-and-skills-bis/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-strengthen-nutritional-healthcare-business-with-acquisition-of-maxinutrition/ https://www.gsk.com/en-gb/media/press-releases/phase-iii-study-in-her2-positive-advanced-breast-cancer-shows-overall-survival-benefit-when-tykerb-is-combined-with-paclitaxel/ https://www.gsk.com/en-gb/media/press-releases/data-from-tykerb-investigational-phase-iii-studies-in-neo-adjuvant-her2-positive-breast-cancer-presented-at-breast-cancer-symposium/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-to-acquire-nanjing-meirui-pharmaceuticals-in-china/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-extension-of-benlysta-pdufa-target-date-to-10th-march-2011/ https://www.gsk.com/en-gb/media/press-releases/avodart-reviewed-by-fda-advisory-committee-for-prostate-cancer-risk-reduction/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-announce-receipt-of-us-fda-complete-response-letter-for-ezogabine/ https://www.gsk.com/en-gb/media/press-releases/government-patent-box-proposals-transform-uk-attractiveness-for-investment/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-increase-its-shareholding-in-theravance/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-jsc-binnopharm-enter-vaccine-production-alliance-in-russia/ https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-vote-of-fda-advisory-committee-to-recommend-approval-of-benlysta-for-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/new-study-findings-show-no-benefit-of-prescription-omega-3-fatty-acids-in-prevention-of-recurrent-symptomatic-atrial-fibrillation-in-affected-patients/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-fiocruz-extend-innovative-collaboration-to-research-and-develop-new-medicines-for-neglected-tropical-diseases/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-approval-in-japan-for-two-medicines-revolade-and-xyzal/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-enter-exclusive-worldwide-agreement-to-develop-and-commercialise-amigal-for-fabry-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-previously-reported-settlement-with-us-department-of-justice-regarding-former-manufacturing-plant/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q3-results-for-2010/ https://www.gsk.com/en-gb/media/press-releases/gsk-outlines-approach-to-delivering-advances-in-the-treatment-of-rare-diseases/ https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-fondazione-san-raffaele-to-collaborate-on-gene-therapy-for-rare-diseases/ https://www.gsk.com/en-gb/media/press-releases/gsk-increases-support-for-who-strategy-to-improve-children-s-health-with-new-5-year-commitment-to-expand-donations-of-albendazole-medicine/ https://www.gsk.com/en-gb/media/press-releases/gsk-takes-minority-stake-in-newly-formed-convergence-pharmaceuticals/ https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-herpevac-trial-for-women-evaluating-simplirix-herpes-simplex-vaccine/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-eu-approval-for-a-new-therapeutic-indication-for-arixtra-fondaparinux/ https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-on-avandia-following-ema-and-fda-reviews/ https://www.gsk.com/en-gb/media/press-releases/gsk-eu-regulatory-update-on-pandemrix/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-combination-icslaba-phase-ii-results-in-the-relovair-development-programme/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-refocus-development-programme-for-ofatumumab-in-autoimmune-indications/ https://www.gsk.com/en-gb/media/press-releases/three-year-results-from-eclipse-study-indicate-that-copd-patients-may-require-prevention-strategies-to-manage-exacerbations-regardless-of-disease-severity/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-bjd-collaborate-on-a-new-educational-programme-to-reduce-global-burden-of-joint-pain/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-start-of-ofatumumab-phase-iii-combination-study-in-non-hodgkin-s-lymphoma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-for-chief-financial-officer/ https://www.gsk.com/en-gb/media/press-releases/galapagos-reaches-agreement-to-acquire-glaxosmithkline-research-centre-in-zagreb-croatia/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-lonza-to-secure-capacity-and-expertise-in-biological-manufacturing-to-support-ongoing-development-of-gsk-s-biopharmaceuticals-portfolio/ https://www.gsk.com/en-gb/media/press-releases/bbc-panorama-6-september-2010/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-pre-broadcast-statement-bbc-panorama-6-september-2010/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-responds-to-british-medical-journal-article-regarding-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/reports-of-narcolepsy-in-europe-following-vaccination-with-pandemrix/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-announce-new-us-fda-pdufa-goal-date-for-ezogabine/ https://www.gsk.com/en-gb/media/press-releases/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-priority-review-designation-for-benlysta-belimumab-as-a-potential-treatment-for-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-topline-results-from-the-concluded-pivotal-trial-of-arzerra-ofatumumab-in-fludarabine-and-alemtuzumab-refractory-chronic-lymphocytic-leukemia/ https://www.gsk.com/en-gb/media/press-releases/image-of-new-antibiotic-in-action-opens-up-new-opportunities-to-combat-antibacterial-resistance/ https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-on-anacor-s-novel-antibiotic-for-the-treatment-of-gram-negative-infections/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-a-new-indication-for-arixtra/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-in-response-to-fda-announcement-on-tide-trial/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q2-results-for-2010/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-legal-update/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-in-response-to-fda-advisory-committees-vote-on-safety-of-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-responds-to-senate-finance-committee-letter-of-12-july-to-fda/ https://www.gsk.com/en-gb/media/press-releases/data-support-avandia-rosiglitazone-maleate-cardiovascular-safety-profile/ https://www.gsk.com/en-gb/media/press-releases/gsk-eu-regulatory-update-on-avandia-rosiglitazone/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-edb-commit-35-million-usd-in-funding-to-support-research-in-green-and-sustainable-manufacturing-in-singapore/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-amendment-to-ofatumumab-agreement/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-creates-a-new-operating-unit-dedicated-to-expanding-access-to-medicines-for-people-living-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-aptuit-finalise-agreement-for-aptuit-to-acquire-gsk-s-research-operations-in-italy/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-eu-authorisation-for-a-new-therapeutic-indication-for-tyverb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-enters-agreement-with-medivir-for-exclusive-rights-to-cold-sore-treatment-xerclear/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-conditional-marketing-authorisation-in-the-eu-for-votrient-pazopanib/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-jalyn-a-fixed-dose-combination-of-dutasteride-and-tamsulosin-for-symptomatic-bph-in-men-with-an-enlarged-prostate/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-complete-response-from-fda-for-candidate-meningococcal-and-hib-combination-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-drives-latin-america-growth-strategy-with-acquisition-of-laboratorios-phoenix/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-bla-filed-for-benlysta-belimumab/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-benlysta-belimumab/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-revised-product-labels-for-serevent-and-advair/ https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-maintains-position-on-the-continued-use-of-rotarix-rotavirus-vaccine/ https://www.gsk.com/en-gb/media/press-releases/viani-seretide-german-patent-litigation-update/ https://www.gsk.com/en-gb/media/press-releases/new-research-identifies-promising-leads-to-follow-in-search-for-medicines-to-fight-malaria/ https://www.gsk.com/en-gb/media/press-releases/fda-says-healthcare-providers-can-resume-use-of-rotarix-rotavirus-vaccine-live-oral/ https://www.gsk.com/en-gb/media/press-releases/patrick-vallance-appointed-to-gsk-executive-leadership-team/ https://www.gsk.com/en-gb/media/press-releases/gsk-extends-presence-in-asia-with-new-strategic-alliance-in-south-korea/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-fda-advisory-committee-meeting-on-rotavirus-vaccines/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q1-results-for-2010/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-conditional-marketing-authorisation-in-the-eu-for-arzerra-ofatumumab/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-isis-pharmaceuticals-collaborate-on-rna-therapeutics-for-rare-and-infectious-diseases/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-duodart/ https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-avodart-dutasteride/ https://www.gsk.com/en-gb/media/press-releases/updated-glaxosmithkline-statement-on-european-regulatory-guidance-relating-to-manufacture-of-rotarix-rotavirus-vaccine/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-joins-global-vaccine-alliance-to-help-prevent-millions-of-children-from-contracting-pneumococcal-disease-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-for-leadership-of-consumer-healthcare-business/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-on-new-information-relating-to-manufacture-of-rotarix-rotavirus-vaccine/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-swiss-approval-of-duodart/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-commences-relovair-phase-iii-asthma-programme/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2009-corporate-responsibility-report/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-marketing-authorisation-in-the-eu-for-revolade-eltrombopag/ https://www.gsk.com/en-gb/media/press-releases/gsk-commences-succession-plan-for-management-of-vaccines-business/ https://www.gsk.com/en-gb/media/press-releases/gsk-ceo-andrew-witty-dedicates-albendazole-facility-in-nashik-to-who-s-global-programme-to-eliminate-lf/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-responds-to-us-senate-committee-on-finance-report-on-avandia/ https://www.gsk.com/en-gb/media/press-releases/gsk-rejects-conclusions-of-senate-committee-on-finance-staff-report-on-avandia/ https://www.gsk.com/en-gb/media/press-releases/gsk-rejects-conclusions-reported-in-the-new-york-times-story-on-avandia/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinions-in-europe-for-tyverb-lapatinib-and-votrient-pazopanib/ https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-fda-s-proposed-label-revisions-for-some-asthma-medicines/ https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-warns-consumers-of-potential-health-risks-associated-with-long-term-excessive-use-of-zinc-containing-denture-adhesives/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-receive-fda-complete-response-letter-for-horizant-gsk1838262xp13512-for-rls/ https://www.gsk.com/en-gb/media/press-releases/gsk-launches-new-specialist-unit-to-research-and-develop-medicines-for-rare-diseases/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-appointment-of-philippe-fauchet-as-president-of-gsk-japan/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2009/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-tykerb-receives-accelerated-approval-for-first-line-combination-treatment-of-hormone-receptor-positive-her2pluserbb2plus-metastatic-breast-cancer/ https://www.gsk.com/en-gb/media/press-releases/rotarix-significantly-reduced-severe-rotavirus-gastroenteritis-in-african-babies-during-their-first-year-of-life/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-open-innovation-strategy-to-help-deliver-new-and-better-medicines-for-people-living-in-the-world-s-poorest-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-contributes-to-haiti-relief-efforts/ https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-to-progress-development-of-chemocentryx-s-traficet-en-for-the-treatment-of-inflammatory-bowel-diseases/ https://www.gsk.com/en-gb/media/press-releases/audio-recording-of-meeting-between-gsk-and-dr-nissen-to-discuss-avandia/ https://www.gsk.com/en-gb/media/press-releases/revolade-eltrombopag-receives-positive-opinion-in-europe-for-chronic-immune-thrombocytopenic-purpura/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-nanobio-announce-otc-licensing-agreement-for-cold-sore-treatment/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-speaking-consulting-fees-paid-to-us-healthcare-professionals/ https://www.gsk.com/en-gb/media/press-releases/gsk-study-showed-targeted-therapy-combination-achieved-14-month-overall-survival-in-patients-with-advanced-breast-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-intercell-form-strategic-alliance-to-develop-and-commercialise-innovative-needle-free-patch-based-vaccines/ https://www.gsk.com/en-gb/media/press-releases/pre-budget-report-response-gsk-comments-on-patent-box/ https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-second-pivotal-phase-iii-trial-for-investigational-cardiovascular-medication-darapladib/ https://www.gsk.com/en-gb/media/press-releases/gsk-update-gsk-s-arepanrix-h1n1-pandemic-vaccine-prequalified-by-the-world-health-organization/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-extension-of-strategic-collaboration-with-aspen/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announced-as-tier-3-sponsor-as-london-2012-anti-doping-plans-confirmed/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-files-rotarix-for-prevention-of-rotavirus-in-japan/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-gilead-announce-agreement-to-commercialise-viread-for-chronic-hepatitis-b-in-key-asian-countries/ https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-avodart/ https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-children-and-adolescents-from-3-to-17-years-of-age/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-nabi-announce-agreement-for-nicvax-a-vaccine-for-nicotine-addiction/ https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-us-fda-approves-gsk-s-pandemic-h1n1-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/ https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-on-co-administration-with-annual-seasonal-influenza-vaccine-fluarix/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-announce-extension-of-gsk1838262-xp13512-fda-review-date-to-9-february-2010/ https://www.gsk.com/en-gb/media/press-releases/world-health-organization-grants-prequalification-for-global-use-to-gsk-s-10-valent-synflorix-vaccine/ https://www.gsk.com/en-gb/media/press-releases/world-s-largest-malaria-vaccine-trial-now-underway-in-seven-african-countries/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-a-new-specialist-hiv-company-dedicated-to-delivering-advances-in-hiv-treatment-and-care/ https://www.gsk.com/en-gb/media/press-releases/retigabine-regulatory-update/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-positive-results-in-second-of-two-phase-3-trials-of-benlysta-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2009/ https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-an-elderly-population/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-theravance-commence-phase-iii-horizon-programme-to-develop-a-next-generation-treatment-for-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-accelerated-approval-for-arzerra/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-experience-of-gsk-s-h1n1-adjuvanted-vaccine-pandemrix-and-preliminary-paediatric-results/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-full-presentation-at-acr-of-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-votrient-for-advanced-renal-cell-cancer/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-cervarix-glaxosmithkline-s-cervical-cancer-vaccine/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-results-from-second-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine-confirm-immune-response-and-tolerability/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-cervarix-becomes-the-first-cervical-cancer-vaccine-to-gain-approval-in-japan/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-us-patent-and-trademark-office-file-a-motion-to-dismiss-litigation-over-final-regulations/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-prosensa-form-alliance-to-fight-duchenne-muscular-dystrophy/ https://www.gsk.com/en-gb/media/press-releases/gsk-expands-presence-in-china-through-strategic-cooperation-to-form-a-joint-venture-on-paediatric-vaccines/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-2009-vaccine/ https://www.gsk.com/en-gb/media/press-releases/positive-phase-ii-results-for-gsk1838262-xp13512-reported-for-subjects-with-post-herpetic-neuralgia-and-a-history-of-inadequate-response-to-gabapentin/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-unanimous-fda-panel-approval-recommendation-for-votrient/ https://www.gsk.com/en-gb/media/press-releases/gsk-partners-with-uk-government-and-wellcome-trust-to-stimulate-innovation-through-the-creation-of-a-world-class-science-park/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-avodart-tamsulosin-combination-showed-benefits-for-men-with-prostate-enlargement/ https://www.gsk.com/en-gb/media/press-releases/avodart-dutasteride-regulatory-update/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-european-commission-approval/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-on-fda-review-of-cervarix/ https://www.gsk.com/en-gb/media/press-releases/fatality-reported-in-uk-hpv-vaccine-immunisation-programme/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-upch-to-launch-lucozade-across-china/ https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-regulatory-filings-for-zunrisarezonic/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-positive-opinion-from-european-regulators/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-initial-results-from-first-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine/ https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1265744-a-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-1-2a-study-in-healthy-and-hiv-infected-subjects/ https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-makes-favorable-recommendation-for-cervarix-glaxosmithkline-s-candidate-cervical-cancer-vaccine/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-results-from-a-study-of-arzerra-in-rituximab-refractory-follicular-nhl/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-brazil-s-fiocruz-form-partnership-for-new-rd-effort-and-increased-vaccine-access/ https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-top-line-results-for-ofatumumab-in-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-mepolizumab-for-the-treatment-of-hypereosinophilic-syndrome-hes/ https://www.gsk.com/en-gb/media/press-releases/amgen-to-collaborate-with-gsk-to-commercialize-denosumab-in-europe-for-postmenopausal-osteoporosis-pmo/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-acquisition-of-stiefel/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2009/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/ https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1349572-the-only-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-2-study/ https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-commitments-to-fight-hivaids-in-sub-saharan-africa-special-focus-on-care-and-treatment-of-children/ https://www.gsk.com/en-gb/media/press-releases/who-grants-prequalification-to-cervarix-gsk-s-vaccine-to-help-combat-cervical-cancer-in-developing-nations/ https://www.gsk.com/en-gb/media/press-releases/alnylam-joins-gsk-in-donating-intellectual-property-to-patent-pool-for-neglected-tropical-diseases/ https://www.gsk.com/en-gb/media/press-releases/gsk-further-extends-its-product-portfolio-in-the-middle-east-and-north-africa/ https://www.gsk.com/en-gb/media/press-releases/seretide-irish-patent-litigation-update/ https://www.gsk.com/en-gb/media/press-releases/regulatory-update-for-rezonic-casopitant-mesylate/ https://www.gsk.com/en-gb/media/press-releases/landmark-study-for-gsk-s-cervical-cancer-vaccine-published-in-the-lancet/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-chroma-therapeutics-form-alliance-to-develop-novel-macrophage-targeted-drugs/ https://www.gsk.com/en-gb/media/press-releases/fda-extends-review-of-arzerra-ofatumumab/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-shenzhen-neptunus-create-new-alliance-to-develop-and-manufacture-influenza-vaccines-in-china/ https://www.gsk.com/en-gb/media/press-releases/large-long-term-study-shows-avandia-has-no-increased-overall-cardiovascular-risk-compared-to-other-commonly-used-diabetes-medicines/ https://www.gsk.com/en-gb/media/press-releases/world-health-organization-grants-global-prequalification-to-gsk-s-rotarix-vaccine/ https://www.gsk.com/en-gb/media/press-releases/positive-results-with-revolade-and-arzerra-for-difficult-to-treat-blood-disorders/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-concert-pharmaceuticals-form-alliance-to-develop-novel-deuterium-modified-drugs/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-pazopanib-significantly-delayed-tumor-progression-in-patients-with-advanced-kidney-cancer/ https://www.gsk.com/en-gb/media/press-releases/fda-advisory-panel-makes-favorable-recommendation-for-arzerra-ofatumumab/ https://www.gsk.com/en-gb/media/press-releases/us-department-of-health-and-human-services-hhs-purchases-gsk-s-a-h1n1-influenza-antigen-and-proprietary-adjuvant-system/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/ https://www.gsk.com/en-gb/media/press-releases/gsk-extends-strategic-collaboration-with-aspen/ https://www.gsk.com/en-gb/media/press-releases/community-healthcare-charities-receive-300-000-from-glaxosmithkline-in-recognition-of-their-work/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-divest-us-rights-for-wellbutrin-xl-to-biovail-for-510-million/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/ https://www.gsk.com/en-gb/media/press-releases/large-long-term-study-shows-dutasteride-reduced-prostate-cancer-risk-in-men-at-increased-risk-of-the-disease/ https://www.gsk.com/en-gb/media/press-releases/emergence-of-a-new-h1n1-influenza-a-strain-swine-influenza/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-launches-alli-orlistat-60-mg/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-stiefel-to-create-new-world-leading-specialist-dermatology-business/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-idenix-pharmaceuticals-sign-worldwide-license-agreement-for-idx899-a-novel-nnrti-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-tyverb-tykerb-lapatinib-for-first-line-treatment-of-metastatic-breast-cancer-in-europe-us/ https://www.gsk.com/en-gb/media/press-releases/cervarix-us-regulatory-update/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-phase-2b-results-for-once-daily-fluticasone-furoate-in-the-treatment-of-asthma/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-changes/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-submit-arzerra-ofatumumab-application-to-fda-for-the-treatment-of-advanced-stage-blood-cancer/ https://www.gsk.com/en-gb/media/press-releases/deirdre-connelly-to-join-gsk-as-president-north-american-pharmaceuticals/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-charges-for-legal-matters/ https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-drive-growth-in-emerging-markets-with-acquisition-of-ucb-products/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-paediatric-pneumococcal-candidate-vaccine-synflorix-receives-positive-opinion-in-europe/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-european-commission-approval-to-market-alli-orlistat-60mg/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-xenoport-resubmit-new-drug-application-for-solzira-in-restless-legs-syndrome/ https://www.gsk.com/en-gb/media/press-releases/synflorix-glaxosmithkline-s-pneumococcal-vaccine-receives-european-authorisation/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2008-corporate-responsibility-report/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-seek-european-marketing-authorisation-of-arzerra-ofatumumab-in-advanced-stage-blood-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-phase-iii-programme-for-novel-type-2-diabetes-medication-syncria-albiglutide/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-submits-european-marketing-authorisation-application-for-pazopanib-in-advanced-kidney-cancer/ https://www.gsk.com/en-gb/media/press-releases/nice-refuses-funding-for-advanced-breast-cancer-treatment-tyverb-lapatinib/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-sale-of-shares-in-quest-diagnostics-inc/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-a-strategic-alliance-with-dr-reddy-s-to-further-accelerate-sales-growth-in-emerging-markets/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2008/ https://www.gsk.com/en-gb/media/press-releases/shionogi-glaxosmithkline-pharmaceuticals-acknowledges-position-of-the-european-aids-treatment-group/ https://www.gsk.com/en-gb/media/press-releases/positive-results-for-relvar-ellipta-lung-function-study-in-patients-with-well-controlled-asthma/ https://www.gsk.com/en-gb/media/press-releases/abbas-hussain-to-leave-gsk/ https://www.gsk.com/en-gb/media/press-releases/luke-miels-appointed-president-global-pharmaceuticals-gsk/ https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/ https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-closure-of-agreement-to-divest-anaesthesia-portfolio-to-aspen/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-musca-study-shows-nucala-mepolizumab-significantly-improves-quality-of-life-and-lung-function-in-severe-asthma-patients-with-an-eosinophilic-phenotype/ https://www.gsk.com/en-gb/media/press-releases/uk-biobank-gsk-and-regeneron-announce-largest-gene-sequencing-initiative-on-world-s-most-detailed-health-database-to-improve-drug-discovery-and-disease-diagnosis/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-scholarships-to-recognise-retiring-ceo-sir-andrew-witty-s-contribution-to-global-health/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-with-mepolizumab-in-patients-with-severe-hypereosinophilic-syndrome/ https://www.gsk.com/en-gb/media/press-releases/gsk-makes-change-to-financial-reporting-framework/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-in-japan-of-its-candidate-vaccine-for-prevention-of-shingles/ https://www.gsk.com/en-gb/media/press-releases/togo-becomes-first-country-in-africa-to-validate-the-elimination-of-lymphatic-filariasis-as-a-public-health-problem/ https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compared-with-their-usual-care/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-phase-iii-results-of-mepolizumab-in-patients-with-severe-chronic-obstructive-pulmonary-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-positive-phase-iii-study-investigating-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-another-quarter-of-continued-progress/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-ats-on-treatment-effect-of-nucala-mepolizumab-in-severe-asthma-according-to-blood-eosinophil-level/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/ https://www.gsk.com/en-gb/media/press-releases/four-innovations-to-tackle-under-five-deaths-win-us-1-million-healthcare-innovation-award-from-gsk-and-save-the-children/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-positive-headline-phase-iii-results-showing-single-dose-tafenoquine-reduces-risk-of-relapse-in-patients-with-plasmodium-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-from-10-year-continuation-study-showing-sustained-disease-control-with-benlysta-belimumab-in-sle/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-results-from-phase-iii-revaccination-study-of-its-candidate-shingles-vaccine-shingrix-at-cdc-s-advisory-meeting/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-with-mepolizumab-in-patients-with-nasal-polyps/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-synflorix-pneumococcal-vaccine-four-dose-vial/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-mepolizumab-in-eosinophilic-granulomatosis-with-polyangiitis-egpa/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-further-progress-in-q2-and-sets-out-new-priorities-for-the-group/ https://www.gsk.com/en-gb/media/press-releases/gsk-updates-on-uk-manufacturing-network/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-board-and-committee-changes/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-eu-filing-for-extended-use-of-relvar-ellipta-in-patients-with-controlled-asthma-on-an-icslaba-combination/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-a-new-self-injectable-formulation-of-benlysta-belimumab-for-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-of-arnuity-ellipta-in-children-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings/ https://www.gsk.com/en-gb/media/press-releases/switching-to-a-dolutegravir-regimen-from-a-boosted-protease-inhibitor-regimen-maintained-viral-suppression-and-improved-lipid-fractions-in-patients-with-hiv-and-high-cardiovascular-risk/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-uk-life-sciences-industrial-strategy/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-respiratory-data-from-pipeline-to-clinical-practice-at-ers/ https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-on-phase-iii-ny-eso-t-cell-therapy-gsk3377794/ https://www.gsk.com/en-gb/media/press-releases/positive-results-from-pioneering-salford-lung-study-in-asthma-published-in-the-lancet-and-presented-at-european-respiratory-congress/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-results-published-in-nejm-of-mepolizumab-in-patients-with-eosinophilic-copd-at-risk-of-exacerbations/ https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-votes-unanimously-for-shingrix-hzsu-in-the-us-for-prevention-of-herpes-zoster-shingles-in-adults-ages-50-and-over/ https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-receives-positive-opinion-from-the-chmp-in-europe-for-appropriate-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-self-injectable-formulation-of-benlysta-for-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-innoviva-report-positive-headline-results-from-impact-study-showing-single-inhaler-triple-therapy-trelegy-ellipta-reduced-copd-exacerbations/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-approval-of-shingrix-in-canada/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-world-health-organization-prequalification-for-synflorix-pneumococcal-vaccine-four-dose-vial/ https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q3-sales-of-78-billion-plus4-aer-plus2-cer/ https://www.gsk.com/en-gb/media/press-releases/cdc-s-advisory-committee-on-immunization-practices-recommends-shingrix-as-the-preferred-vaccine-for-the-prevention-of-shingles-for-adults-aged-50-and-up/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/public-private-consortium-aims-to-cut-preclinical-cancer-drug-discovery-from-six-years-to-just-one/ https://www.gsk.com/en-gb/media/press-releases/gsk-study-demonstrates-superiority-of-anoro-ellipta-to-stiolto-respimat-in-improving-lung-function-in-chronic-obstructive-pulmonary-disease/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-bcma-antibody-drug-conjugate-receives-breakthrough-therapy-designation-from-us-fda-for-relapsed-and-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-application-for-mepolizumab-in-eosinophilic-chronic-obstructive-pulmonary-disease-copd/ https://www.gsk.com/en-gb/media/press-releases/first-long-term-efficacy-analysis-on-the-effect-of-gsk-s-benlysta-on-rate-of-organ-damage-progression-in-sle-versus-standard-therapy-alone/ https://www.gsk.com/en-gb/media/press-releases/patrick-vallance-president-rd-gsk-to-become-uk-governments-chief-scientific-adviser/ https://www.gsk.com/en-gb/media/press-releases/dr-hal-barron-appointed-chief-scientific-officer-and-president-research-development-gsk/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/ https://www.gsk.com/en-gb/media/press-releases/juluca-approved-in-us-as-first-2-drug-regimen-once-daily-single-pill/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-landmark-impact-data-to-us-regulatory-authority-to-support-expanded-label-for-trelegy-ellipta/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-uk-industrial-strategy/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-application-for-single-dose-tafenoquine-for-plasmodium-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/ https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-launch-of-the-uk-government-s-life-sciences-sector-deal/ https://www.gsk.com/en-gb/media/press-releases/new-data-supports-the-safety-and-efficacy-of-gsk-s-shingrix-in-preventing-shingles-in-autologous-haematopoietic-stem-cell-transplant-patients/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-new-data-for-priority-bcma-asset-from-its-emerging-oncology-pipeline-at-59th-ash-meeting/ https://www.gsk.com/en-gb/media/press-releases/gsk-achieves-approval-for-nucala-mepolizumab-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-for-adults-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-single-dose-tafenoquine-for-the-treatment-of-plasmodium-vivax-malaria-to-australia-s-therapeutic-goods-administration/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-us-label-update-on-icslaba-combinations-in-asthma-based-on-review-of-safety-data/ https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-the-amr-benchmark/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-chmp-positive-opinion-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-receives-positive-opinion-from-the-chmp-in-europe-for-the-prevention-of-shingles-in-adults-aged-50-and-over/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-improvements-in-sales-margins-and-cash-flow-in-2017/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-landmark-impact-data-to-european-medicines-agency-to-support-expanded-label-for-trelegy-ellipta/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-expanded-indication-for-fluarix-tetra-influenza-vaccine-for-ages-six-months-and-older/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-improved-asthma-control-in-patients-uncontrolled-on-xolair-omalizumab/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/ https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-eu-approval-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-of-benlysta-and-rituximab-combination-in-systemic-lupus-erythematosus/ https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over/ https://www.gsk.com/en-gb/media/press-releases/gsk-update-regarding-pfizer-inc-consumer-healthcare/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ https://www.gsk.com/en-gb/media/press-releases/gsk-signs-strategic-agreement-to-transfer-rare-disease-gene-therapy-portfolio-to-orchard-therapeutics/ https://www.gsk.com/en-gb/media/press-releases/landmark-impact-study-published-in-nejm-shows-significant-benefits-of-trelegy-ellipta-for-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-kevin-sin-as-new-svp-and-head-of-worldwide-business-development-for-rd/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q1-sales-of-72-billion-2-aer-plus4-cer/ https://www.gsk.com/en-gb/media/press-releases/once-daily-trelegy-ellipta-gains-expanded-indication-in-the-us-for-the-treatment-of-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/simon-dingemans-chief-financial-officer-to-retire-from-gsk/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-industry-leading-respiratory-research-and-scientific-innovation-showcased-at-ats-conference/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-study-reports-long-term-safety-data-consistent-exacerbation-reduction-and-improved-asthma-control/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-consumer-healthcare-buyout/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-vaccines-and-global-manufacturing-supply-leadership/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-results-showing-low-rates-of-organ-damage-with-long-term-use-of-benlysta/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine-demonstrating-the-ability-to-control-hiv-with-a-two-drug-regimen-in-treatment-naïve-patients/ https://www.gsk.com/en-gb/media/press-releases/infants-may-now-be-protected-against-meningitis-b-with-fewer-doses-adding-flexibility-to-vaccination-schedules/ https://www.gsk.com/en-gb/media/press-releases/roivant-subsidiary-dermavant-sciences-signs-agreement-with-gsk-to-purchase-rights-to-tapinarof/ https://www.gsk.com/en-gb/media/press-releases/james-ford-appointed-gsk-general-counsel/ https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-endorses-the-effectiveness-and-safety-of-single-dose-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/ https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data-at-aids-2018-from-landmark-gemini-studies/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-improvements-in-sales-margins-and-cash-flow-in-q2-2018/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-programme-to-gsk/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/ https://www.gsk.com/en-gb/media/press-releases/gsk-reports-on-outcome-of-the-fda-advisory-committee-on-mepolizumab-for-the-treatment-of-copd-patients-on-maximum-inhaled-therapy/ https://www.gsk.com/en-gb/media/press-releases/chmp-recommend-nucala-mepolizumab-for-the-treatment-of-severe-eosinophilic-asthma-paediatric-patients-in-europe/ https://www.gsk.com/en-gb/media/press-releases/iain-mackay-appointed-gsk-chief-financial-officer/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/ https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-complete-response-letter-from-us-fda-for-use-of-mepolizumab-in-copd-patients/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-of-indirect-treatment-comparisons-of-nucala-to-benralizumab-and-reslizumab-for-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-data-presented-at-ers-further-supports-its-industry-leading-respiratory-medicines-portfolio/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-receives-positive-chmp-opinion-supporting-expanded-copd-indication-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-tres-cantos-open-lab-foundation-announce-additional-5m-funding-for-open-innovation-research-in-diseases-impacting-the-developing-world/ https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-helps-prevent-active-pulmonary-tuberculosis-in-hiv-negative-adults-in-phase-ii-study/ https://www.gsk.com/en-gb/media/press-releases/positive-results-from-harmony-outcomes-study-of-albiglutide-published-in-the-lancet/ https://www.gsk.com/en-gb/media/press-releases/gsk-updates-policy-for-working-with-healthcare-professionals/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-efficacy-and-safety-data-of-an-anti-gm-csf-antibody-in-patients-with-rheumatoid-arthritis/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-3-results-for-daprodustat-in-patients-with-anaemia-associated-with-chronic-kidney-disease/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q3-sales-of-81-billion-plus3-aer-plus6-cer/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-at-48-weeks-in-heavily-treatment-experienced-patients-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/statement-gsk-supports-gold-committee-s-efforts-to-further-personalise-copd-management/ https://www.gsk.com/en-gb/media/press-releases/once-daily-trelegy-ellipta-gains-expanded-copd-indication-in-europe/ https://www.gsk.com/en-gb/media/press-releases/kozenis-tafenoquine-approved-by-the-australian-therapeutic-goods-administration-for-the-radical-cure-of-p-vivax-malaria/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-to-expand-the-use-of-nucala-in-children-with-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/ https://www.gsk.com/en-gb/media/press-releases/access-to-medicine-index-2018-media-statement/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-kyowa-hakko-kirin-sign-strategic-commercialisation-deal-in-japan-for-daprodustat-a-potential-new-oral-treatment-for-anaemia-associated-with-chronic-kidney-disease/ https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-horlicks-and-other-consumer-healthcare-nutrition-products-to-unilever/ https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-tesaro-an-oncology-focused-biopharmaceutical-company/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-and-pfizer-inc-to-form-new-world-leading-consumer-healthcare-joint-venture/ https://www.gsk.com/en-gb/media/press-releases/two-positive-phase-iii-studies-of-tafenoquine-for-the-radical-cure-of-plasmodium-vivax-malaria-published-in-the-new-england-journal-of-medicine/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-to-appoint-new-chairman/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-kgaa-darmstadt-germany-announce-global-alliance-to-jointly-develop-and-commercialise-m7824-a-novel-immunotherapy-with-potential-in-multiple-difficult-to-treat-cancers/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-earnings-and-cash-flow-growth-in-2018/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-a-positive-chmp-opinion-for-intravenous-zanamivir-for-the-treatment-of-complicated-influenza/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-two-pivotal-phase-iii-studies/ https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-positive-data-from-dreamm-1-study-of-anti-bcma-antibody-drug-conjugate/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/ https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-product-sales-reporting-changes-and-the-impact-of-ifrs-16-leases/ https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naïve-hiv-1-adults/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravirlamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-benlysta-for-intravenous-use-in-children-with-lupus-aged-five-years-and-above/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-of-77-billion-plus6-aer-plus5-cer/ https://www.gsk.com/en-gb/media/press-releases/phase-iii-captain-study-of-trelegy-ellipta-in-patients-with-asthma-meets-primary-endpoint/ https://www.gsk.com/en-gb/media/press-releases/update-on-consumer-healthcare-joint-venture-with-pfizer/ https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/ https://www.gsk.com/en-gb/media/press-releases/gsk-changes-sales-representative-incentive-programme/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-new-self-administration-options/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-on-anti-bcma-antibody-drug-conjugate-in-patients-with-relapsedrefractory-multiple-myeloma-to-be-presented-at-european-hematology-association-eha-congress/ https://www.gsk.com/en-gb/media/press-releases/gsk-joins-forces-with-the-university-of-california-to-advance-genomic-research-and-improve-drug-discovery/ https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-gsk-s-application-for-zejula-niraparib-in-late-stage-ovarian-cancer-with-priority-review/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-start-for-its-anti-gm-csf-antibody-otilimab-in-patients-with-rheumatoid-arthritis-ra/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice/ https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-the-uk-trial-of-subscription-style-payment-system-for-pharma-companies-to-incentivise-creation-of-new-antibiotics/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-prima-study-of-zejula-niraparib-for-patients-with-ovarian-cancer-in-the-first-line-maintenance-setting/ https://www.gsk.com/en-gb/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-96-week-data-from-phase-iii-study-of-investigational-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv-at-ias-2019/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/ https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-jonathan-symonds-as-non-executive-chairman-of-the-board-of-directors/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-and-earnings-growth-in-q2-2019/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine/ https://www.gsk.com/en-gb/media/press-releases/five-years-on-39-million-people-in-the-developing-world-have-access-to-hiv-treatment-dolutegravir-thanks-to-access-oriented-voluntary-licensing-agreements/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/ https://www.gsk.com/en-gb/media/press-releases/nucala-receives-eu-approval-for-self-administration-by-patients-with-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-leadership-changes-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-first-regulatory-application-for-daprodustat-in-japan-for-patients-with-renal-anaemia-due-to-chronic-kidney-disease/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-the-pivotal-dreamm-2-study-for-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-to-present-data-from-its-innovative-oncology-portfolio-at-esmo-congress-2019/ https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-intravenous-benlysta-in-children-with-lupus-aged-five-years-and-above/ https://www.gsk.com/en-gb/media/press-releases/real-world-effectiveness-evidence-among-gsk-data-presented-at-ers-2019/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-showing-promising-anti-tumour-activity-with-gsk3359609-an-icos-receptor-agonist-in-combination-with-pembrolizumab-in-head-and-neck-squamous-cell-carcinoma-hnscc/ https://www.gsk.com/en-gb/media/press-releases/phase-3-prima-trial-of-zejula-niraparib-is-the-first-study-to-show-a-parp-inhibitor-significantly-improves-pfs-regardless-of-biomarker-status/ https://www.gsk.com/en-gb/media/press-releases/nucala-significantly-reduces-exacerbations-in-first-global-prospective-real-world-study-of-a-biologic-in-severe-eosinophilic-asthma/ https://www.gsk.com/en-gb/media/press-releases/idweek-2019-viiv-healthcare-to-present-20-abstracts-from-its-innovative-rd-portfolio-with-focus-on-2-drug-and-long-acting-regimens-and-mental-health-impact-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-submits-filing-to-fda-for-trelegy-ellipta-use-in-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/ https://www.gsk.com/en-gb/media/press-releases/global-fund-replenishment-2019-media-statement/ https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-a-phase-iii-clinical-programme-for-a-potential-first-in-class-antibiotic-gepotidacin/ https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-demonstrates-sustained-level-of-protection-against-active-pulmonary-tuberculosis/ https://www.gsk.com/en-gb/media/press-releases/intravenous-benlysta-is-the-first-biologic-treatment-to-be-approved-for-children-with-lupus-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-of-94-billion-plus16-aer-plus11-cer-pro-forma-plus6-cerstar/ https://www.gsk.com/en-gb/media/press-releases/eacs-2019-viiv-healthcare-to-present-17-abstracts-from-its-portfolio-addressing-the-diverse-needs-of-people-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-is-the-first-treatment-to-show-a-significant-reduction-in-flares-for-patients-with-hypereosinophilic-syndrome-hes/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-bnab-with-potential-for-long-acting-hiv-treatment-and-prevention/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-dtg-for-children-living-with-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-nutritional-products-divestment/ https://www.gsk.com/en-gb/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ https://www.gsk.com/en-gb/media/press-releases/dovato-dolutegravirlamivudine-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/ https://www.gsk.com/en-gb/media/press-releases/deborah-waterhouse-ceo-of-viiv-healthcare-to-join-gsk-corporate-executive-team-cet/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir/ https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/world-s-first-meningitis-b-national-infant-vaccination-programme-shows-75-drop-in-cases-over-three-years/ https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-european-medicines-agency-ema-accepted-marketing-authorisation-application-for-belantamab-mafodotin-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-2019-sales-of-338-billion-plus10-aer-plus8-cer-pro-forma-plus4-cerstar/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states/ https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system/ https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-gsk-s-snda-application-for-zejula-niraparib-for-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer/ https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-accepts-submission-of-gsk-s-marketing-authorisation-application-for-zejula-niraparib-in-first-line-maintenance-treatment/ https://www.gsk.com/en-gb/media/press-releases/first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatment-regimens-for-tuberculosis/ https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-ec-approval-for-the-sale-of-thermacare/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-advil-dual-action-with-acetaminophen-for-over-the-counter-use-in-the-united-states/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-long-term-data-from-phase-iii-study-demonstrating-efficacy-and-safety-of-cabotegravir-and-rilpivirine/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-unc-chapel-hill-announce-five-year-renewal-of-innovative-hiv-cure-partnership/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-first-global-regulatory-approval-of-cabenuva-the-first-complete-long-acting-regimen-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-charles-bancroft-to-the-board-as-a-non-executive-director/ https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-horlicks-and-other-consumer-healthcare-nutrition-products-in-india-and-certain-other-markets/ https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-is-the-first-anti-il5-biologic-to-report-positive-phase-3-results-in-patients-with-nasal-polyps/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-from-the-garnet-study-demonstrating-potential-of-dostarlimab-to-treat-a-subset-of-women-with-recurrent-or-advanced-endometrial-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q1-sales-91-billion-plus19-aer-plus19-cer-proforma-plus10-cerstar/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/ https://www.gsk.com/en-gb/media/press-releases/global-hiv-prevention-study-to-stop-early-after-viiv-healthcare-s-long-acting-injectable-formulation-of-cabotegravir-dosed-every-two-months-shows-higher-efficacy-than-daily-oral-prep/ https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-scientific-innovation-and-advances-in-its-growing-oncology-portfolio-at-asco-2020/ https://www.gsk.com/en-gb/media/press-releases/gsk-partners-with-samsung-biologics/ https://www.gsk.com/en-gb/media/press-releases/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome-hes/ https://www.gsk.com/en-gb/media/press-releases/dreamm-2-and-dreamm-6-data-at-asco-reinforce-the-potential-of-gsk-s-investigational-belantamab-mafodotin/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-intention-to-produce-1-billion-doses-of-pandemic-vaccine-adjuvant/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-data-presentations-from-the-dreamm-programme/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-the-first-ever-dispersible-tablet-formulation-of-dolutegravir/ https://www.gsk.com/en-gb/media/press-releases/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-proposed-unregistered-offering-of-senior-notes-exchangeable-into-theravance-biopharma-ordinary-shares/ https://www.gsk.com/en-gb/media/press-releases/gsk-prices-280-336-000-senior-notes-due-2023-exchangeable-into-theravance-biopharma-ordinary-shares/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-advisory-committee-meeting-to-review-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsedrefractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-covid-19-vaccine-development-collaboration-with-clover-biopharmaceuticals-begins-clinical-trials/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-at-aids-2020-virtual/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-implementation-research-study-on-how-best-to-integrate-an-investigational-once-monthly-injectable-hiv-treatment-in-us-healthcare-practices/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-superior-efficacy-of-investigational-long-acting-injectable-formulation-of-cabotegravir-dosed-every-two-months-over-daily-oral-prep/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-advisory-committee-votes-in-favour-of-positive-benefitrisk-profile-for-belantamab-mafodotin-for-patients-with-relapsedrefractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/ https://www.gsk.com/en-gb/media/press-releases/covid-19-prompts-increased-focus-on-self-care-with-europeans-taking-their-health-more-seriously-to-relieve-pressure-on-healthcare-systems/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-approval-of-belantamab-mafodotin-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q2-sales-of-76-billion-2-aer-3-cer-pro-forma-10-cerstar/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-participant-vaccinated-in-phase-3-clinical-trials-of-its-5-in-1-meningitis-abcwy-vaccine-candidate/ https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-blenrep-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/ https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-scientific-advances-across-its-growing-oncology-portfolio-at-esmo-virtual-congress-2020/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-implementation-science-study/ https://www.gsk.com/en-gb/media/press-releases/fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes/ https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-intent-to-supply-covax-with-at-least-200-million-doses-of-adjuvanted-covid-19-vaccine/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-long-term-safety-and-efficacy-data-for-2-drug-regimen-dovato-dolutegravirlamivudine-alongside-other-key-research-advances-at-the-hiv-glasgow-2020-congress/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/ https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-long-term-switch-data-for-dovato/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-positive-chmp-opinion-for-long-acting-regimen-for-the-treatment-of-hiv/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-clinical-data-on-maternal-and-older-adults-rsv-candidate-vaccines/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-analysis-showing-no-antiretroviral-therapy-interruptions-due-to-covid-19/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-continued-positive-findings-from-first-ever-implementation-science-study/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-new-findings-from-two-studies-of-its-investigational-long-acting-regimen-of-cabotegravir-and-rilpivirine/ https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-resilient-performance-strong-commercial-execution-and-further-strategic-progress-in-q3/ https://www.gsk.com/en-gb/media/press-releases/gsk-nucala-mepolizumab-filings-accepted-by-european-medicines-agency-for-three-additional-eosinophil-driven-diseases/ https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-in-advanced-ovarian-cancer/ https://www.gsk.com/en-gb/media/press-releases/gsk-sets-new-environmental-goals-of-net-zero-impact-on-climate-and-net-positive-impact-on-nature-by-2030/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-investigational-injectable-cabotegravir-is-superior-to-oral-standard-of-care-for-hiv-prevention-in-women/ https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-progress-from-the-blenrep-belantamab-mafodotin-blmf-development-programme-in-multiple-myeloma-at-ash-annual-meeting/ https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe/ https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-2b-data-on-linerixibat-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc/ https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-present-positive-data-on-treatment-for-plasmodium-vivax-malaria-in-children-from-6-months-up-to-15-years-of-age/ https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-breakthrough-therapy-designation-for-investigational-long-acting-cabotegravir-for-hiv-prevention/ https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/ https://www.gsk.com/en-gb/media/press-releases/fda-accepts-gsk-s-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps/ https://www.gsk.com/en-gb/media/resource-centre/ https://www.gsk.com/en-gb/media/resource-centre/our-approach-to-brexit/ https://www.gsk.com/en-gb/media/resource-centre/pharmaceuticals-resources/ https://www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov/ https://www.gsk.com/en-gb/media/resource-centre/covid-19-prompts-increased-focus-on-self-care/ https://www.gsk.com/en-gb/media/resource-centre/vaccine-resources/ https://www.gsk.com/en-gb/media/social-media/ https://www.gsk.com/en-gb/media/rss-feeds/ https://www.gsk.com/en-gb/media/image-and-video-library/ https://www.gsk.com/en-gb/media/media-contact-details/ https://www.gsk.com/en-gb/research-and-development/ https://www.gsk.com/en-gb/research-and-development/our-approach-to-rd/ https://www.gsk.com/en-gb/research-and-development/our-pipeline/ https://www.gsk.com/en-gb/research-and-development/research/ https://www.gsk.com/en-gb/research-and-development/research/how-we-research-new-medicines/ https://www.gsk.com/en-gb/research-and-development/research/how-we-research-new-vaccines/ https://www.gsk.com/en-gb/research-and-development/development/ https://www.gsk.com/en-gb/research-and-development/development/our-focus-areas/ https://www.gsk.com/en-gb/research-and-development/development/how-we-develop-new-medicines/ https://www.gsk.com/en-gb/research-and-development/development/how-we-develop-new-vaccines/ https://www.gsk.com/en-gb/research-and-development/partnerships/ https://www.gsk.com/en-gb/research-and-development/partnerships/our-areas-of-interest/ https://www.gsk.com/en-gb/research-and-development/partnerships/our-approach-to-partnering/ https://www.gsk.com/en-gb/research-and-development/partnerships/supported-studies/ https://www.gsk.com/en-gb/research-and-development/partnerships/business-development/ https://www.gsk.com/en-gb/research-and-development/partnerships/academic-collaborations/ https://www.gsk.com/en-gb/research-and-development/partnerships/venture-funds/ https://www.gsk.com/en-gb/research-and-development/partnerships/contact-us-submit-an-idea/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/gsk-study-register-and-patient-level-data/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/clinical-trial-phases/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/become-a-clinical-research-volunteer/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/data-transparency/ https://www.gsk.com/en-gb/research-and-development/trials-in-people/compassionate-use-expanded-access/ https://www.gsk.com/en-gb/research-and-development/our-use-of-animals/ https://www.gsk.com/en-gb/research-and-development/our-use-of-animals/the-3rs-in-medicine-research/ https://www.gsk.com/en-gb/research-and-development/our-use-of-animals/use-of-non-human-primates/ https://www.gsk.com/en-gb/research-and-development/our-use-of-animals/frequently-asked-questions/ https://www.gsk.com/en-gb/research-and-development/consumer-healthcare-research/ https://www.gsk.com/en-gb/research-and-development/rd-locations/ https://www.gsk.com/en-gb/responsibility/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/using-our-science-for-global-health/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/preparing-for-future-disease-threats/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/pricing-and-access-strategies/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/prevention-awareness-and-infrastructure/ https://www.gsk.com/en-gb/responsibility/improving-health-globally/pull-the-science-2020-antimicrobial-resistance-benchmark/ https://www.gsk.com/en-gb/responsibility/environment-our-new-approach/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/ethics-and-values/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/patient-safety-and-reliable-supply/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/research-practices/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/engaging-with-healthcare-professionals/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/sales-representative-incentive-programme/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/public-policy-and-patient-advocacy/ https://www.gsk.com/en-gb/responsibility/operating-responsibly/human-rights-and-modern-slavery/ https://www.gsk.com/en-gb/responsibility/our-people/ https://www.gsk.com/en-gb/responsibility/our-people/inclusion-and-diversity-at-gsk/ https://www.gsk.com/en-gb/responsibility/our-people/employee-engagement/ https://www.gsk.com/en-gb/responsibility/our-people/health-and-wellbeing/ https://www.gsk.com/en-gb/responsibility/our-people/learning-and-development/ https://www.gsk.com/en-gb/responsibility/environment/ https://www.gsk.com/en-gb/responsibility/environment/carbon/ https://www.gsk.com/en-gb/responsibility/environment/water/ https://www.gsk.com/en-gb/responsibility/environment/waste/ https://www.gsk.com/en-gb/responsibility/environment/environmental-stewardship/ https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/ https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/reporting-archive-and-resources/ https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/charitable-grants/ https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/trade-association-memberships/ https://www.gsk.com/en-gb/responsibility/responsibility-reports-data/patient-group-funding/ https://www.gsk.com/en-gb/contact-us/ https://www.gsk.com/en-gb/contact-us/headquarters/ https://www.gsk.com/en-gb/contact-us/careers/ https://www.gsk.com/en-gb/contact-us/customerspatients/ https://www.gsk.com/en-gb/contact-us/funding-requests/ https://www.gsk.com/en-gb/contact-us/partnerships/ https://www.gsk.com/en-gb/contact-us/partnerships/business-development/ https://www.gsk.com/en-gb/contact-us/partnerships/academia/ https://www.gsk.com/en-gb/contact-us/partnerships/neglected-tropical-diseases/ https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/ https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/enquiries-privacy-notice/ https://www.gsk.com/en-gb/contact-us/worldwide/ https://www.gsk.com/en-gb/contact-us/worldwide/albania/ https://www.gsk.com/en-gb/contact-us/worldwide/algeria/ https://www.gsk.com/en-gb/contact-us/worldwide/argentina/ https://www.gsk.com/en-gb/contact-us/worldwide/australia/ https://www.gsk.com/en-gb/contact-us/worldwide/austria/ https://www.gsk.com/en-gb/contact-us/worldwide/bangladesh/ https://www.gsk.com/en-gb/contact-us/worldwide/belarus/ https://www.gsk.com/en-gb/contact-us/worldwide/belgium/ https://www.gsk.com/en-gb/contact-us/worldwide/bosnia-herz/ https://www.gsk.com/en-gb/contact-us/worldwide/brazil/ https://www.gsk.com/en-gb/contact-us/worldwide/bulgaria/ https://www.gsk.com/en-gb/contact-us/worldwide/cambodia/ https://www.gsk.com/en-gb/contact-us/worldwide/canada/ https://www.gsk.com/en-gb/contact-us/worldwide/caribbean-islands/ https://www.gsk.com/en-gb/contact-us/worldwide/chile/ https://www.gsk.com/en-gb/contact-us/worldwide/costa-rica/ https://www.gsk.com/en-gb/contact-us/worldwide/china-mainland/ https://www.gsk.com/en-gb/contact-us/worldwide/colombia/ https://www.gsk.com/en-gb/contact-us/worldwide/croatia/ https://www.gsk.com/en-gb/contact-us/worldwide/cyprus/ https://www.gsk.com/en-gb/contact-us/worldwide/czech-republic/ https://www.gsk.com/en-gb/contact-us/worldwide/denmark/ https://www.gsk.com/en-gb/contact-us/worldwide/estonia/ https://www.gsk.com/en-gb/contact-us/worldwide/dominican-republic/ https://www.gsk.com/en-gb/contact-us/worldwide/ecuador/ https://www.gsk.com/en-gb/contact-us/worldwide/egypt/ https://www.gsk.com/en-gb/contact-us/worldwide/el-salvador/ https://www.gsk.com/en-gb/contact-us/worldwide/finland/ https://www.gsk.com/en-gb/contact-us/worldwide/france/ https://www.gsk.com/en-gb/contact-us/worldwide/germany/ https://www.gsk.com/en-gb/contact-us/worldwide/greece/ https://www.gsk.com/en-gb/contact-us/worldwide/hong-kong-and-macau/ https://www.gsk.com/en-gb/contact-us/worldwide/guatemala/ https://www.gsk.com/en-gb/contact-us/worldwide/honduras/ https://www.gsk.com/en-gb/contact-us/worldwide/hungary/ https://www.gsk.com/en-gb/contact-us/worldwide/indonesia/ https://www.gsk.com/en-gb/contact-us/worldwide/india/ https://www.gsk.com/en-gb/contact-us/worldwide/ireland/ https://www.gsk.com/en-gb/contact-us/worldwide/italy/ https://www.gsk.com/en-gb/contact-us/worldwide/israel/ https://www.gsk.com/en-gb/contact-us/worldwide/jamaica/ https://www.gsk.com/en-gb/contact-us/worldwide/kazakhstan/ https://www.gsk.com/en-gb/contact-us/worldwide/japan/ https://www.gsk.com/en-gb/contact-us/worldwide/kenya/ https://www.gsk.com/en-gb/contact-us/worldwide/korea/ https://www.gsk.com/en-gb/contact-us/worldwide/latvia/ https://www.gsk.com/en-gb/contact-us/worldwide/lithuania/ https://www.gsk.com/en-gb/contact-us/worldwide/mexico/ https://www.gsk.com/en-gb/contact-us/worldwide/morocco/ https://www.gsk.com/en-gb/contact-us/worldwide/macedonia/ https://www.gsk.com/en-gb/contact-us/worldwide/malaysia/ https://www.gsk.com/en-gb/contact-us/worldwide/malta/ https://www.gsk.com/en-gb/contact-us/worldwide/mauritius/ https://www.gsk.com/en-gb/contact-us/worldwide/myanmar/ https://www.gsk.com/en-gb/contact-us/worldwide/netherlands/ https://www.gsk.com/en-gb/contact-us/worldwide/new-zealand/ https://www.gsk.com/en-gb/contact-us/worldwide/nigeria/ https://www.gsk.com/en-gb/contact-us/worldwide/pakistan/ https://www.gsk.com/en-gb/contact-us/worldwide/peru/ https://www.gsk.com/en-gb/contact-us/worldwide/norway/ https://www.gsk.com/en-gb/contact-us/worldwide/poland/ https://www.gsk.com/en-gb/contact-us/worldwide/portugal/ https://www.gsk.com/en-gb/contact-us/worldwide/panama/ https://www.gsk.com/en-gb/contact-us/worldwide/philippines/ https://www.gsk.com/en-gb/contact-us/worldwide/russia/ https://www.gsk.com/en-gb/contact-us/worldwide/saudi-arabia/ https://www.gsk.com/en-gb/contact-us/worldwide/romania/ https://www.gsk.com/en-gb/contact-us/worldwide/serbia/ https://www.gsk.com/en-gb/contact-us/worldwide/south-africa/ https://www.gsk.com/en-gb/contact-us/worldwide/singapore/ https://www.gsk.com/en-gb/contact-us/worldwide/spain/ https://www.gsk.com/en-gb/contact-us/worldwide/sri-lanka/ https://www.gsk.com/en-gb/contact-us/worldwide/slovakia/ https://www.gsk.com/en-gb/contact-us/worldwide/slovenia/ https://www.gsk.com/en-gb/contact-us/worldwide/sweden/ https://www.gsk.com/en-gb/contact-us/worldwide/switzerland/ https://www.gsk.com/en-gb/contact-us/worldwide/taiwan/ https://www.gsk.com/en-gb/contact-us/worldwide/thailand/ https://www.gsk.com/en-gb/contact-us/worldwide/trinidad-tobago/ https://www.gsk.com/en-gb/contact-us/worldwide/turkey/ https://www.gsk.com/en-gb/contact-us/worldwide/tunisia/ https://www.gsk.com/en-gb/contact-us/worldwide/united-arab-emirates/ https://www.gsk.com/en-gb/contact-us/worldwide/united-states/ https://www.gsk.com/en-gb/contact-us/worldwide/uruguay/ https://www.gsk.com/en-gb/contact-us/worldwide/ukraine/ https://www.gsk.com/en-gb/contact-us/worldwide/venezuela/ https://www.gsk.com/en-gb/contact-us/worldwide/luxembourg/ https://www.gsk.com/en-gb/contact-us/worldwide/united-kingdom/ https://www.gsk.com/en-gb/contact-us/worldwide/jordan/ https://www.gsk.com/en-gb/contact-us/worldwide/lebanon/ https://www.gsk.com/en-gb/contact-us/worldwide/vietnam/ https://www.gsk.com/en-gb/contact-us/worldwide/iran/ https://www.gsk.com/en-gb/contact-us/worldwide/montenegro/ https://www.gsk.com/en-gb/contact-us/worldwide/macau/ https://www.gsk.com/en-gb/behind-the-science/ https://www.gsk.com/en-gb/behind-the-science/tags-a-z/ https://www.gsk.com/en-gb/behind-the-science/innovation/ https://www.gsk.com/en-gb/behind-the-science/innovation/neuroscience-on-the-brain/ https://www.gsk.com/en-gb/behind-the-science/innovation/targeting-the-immune-system-through-open-innovation/ https://www.gsk.com/en-gb/behind-the-science/innovation/turbocharging-the-effect-of-vaccines/ https://www.gsk.com/en-gb/behind-the-science/innovation/our-focus-on-developing-the-next-generation-of-antibiotics/ https://www.gsk.com/en-gb/behind-the-science/innovation/outgrowing-asthma-rooting-out-the-reasons-for-asthma-remission/ https://www.gsk.com/en-gb/behind-the-science/innovation/getting-on-target-in-autoimmune-diseases/ https://www.gsk.com/en-gb/behind-the-science/innovation/copd-our-relentless-pursuit-for-better-breathing/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-genomics-is-driving-a-new-era-of-drug-discovery/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-do-consumer-insights-fuel-our-innovation/ https://www.gsk.com/en-gb/behind-the-science/innovation/vaccine-manufacture-it-s-complicated/ https://www.gsk.com/en-gb/behind-the-science/innovation/welcome-to-the-golden-age-of-vaccine-innovation/ https://www.gsk.com/en-gb/behind-the-science/innovation/tb-uniting-scientists-to-tackle-one-of-the-world-s-biggest-killers/ https://www.gsk.com/en-gb/behind-the-science/innovation/inhaler-innovation-more-than-a-simple-piece-of-plastic/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-a-chance-encounter-led-to-a-world-first-toothpaste/ https://www.gsk.com/en-gb/behind-the-science/innovation/scientists-or-detectives-seeking-new-clues-in-copd/ https://www.gsk.com/en-gb/behind-the-science/innovation/from-bench-to-bedside-lessons-in-converting-science-into-impact/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-smart-is-your-inhaler/ https://www.gsk.com/en-gb/behind-the-science/innovation/asthma-management-it-s-time-to-get-personal/ https://www.gsk.com/en-gb/behind-the-science/innovation/we-need-more-women-in-science-to-create-the-inclusive-technologies-of-the-future/ https://www.gsk.com/en-gb/behind-the-science/innovation/the-digitalisation-lab-bringing-the-digital-age-to-manufacturing/ https://www.gsk.com/en-gb/behind-the-science/innovation/lupus-the-search-for-a-cure-continues/ https://www.gsk.com/en-gb/behind-the-science/innovation/from-eucalyptus-toothpaste-to-a-brew-for-the-flu-tailoring-products-to-different-tastes/ https://www.gsk.com/en-gb/behind-the-science/innovation/you-me-and-23andme-discovering-new-medicines-through-genetics/ https://www.gsk.com/en-gb/behind-the-science/innovation/unravelling-the-mysteries-of-the-human-genome-with-functional-genomics/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-are-we-redefining-research-in-hiv/ https://www.gsk.com/en-gb/behind-the-science/innovation/inside-the-open-lab/ https://www.gsk.com/en-gb/behind-the-science/innovation/tackling-tomorrow-s-health-challenges-today/ https://www.gsk.com/en-gb/behind-the-science/innovation/how-do-you-test-medicines-in-the-real-world/ https://www.gsk.com/en-gb/behind-the-science/innovation/cancer-gets-a-sting-with-new-discovery/ https://www.gsk.com/en-gb/behind-the-science/innovation/delivering-potentially-transformational-medicines-through-rd-innovation-in-oncology/ https://www.gsk.com/en-gb/behind-the-science/innovation/making-the-switch-how-we-re-improving-access-to-proven-medicines/ https://www.gsk.com/en-gb/behind-the-science/innovation/gsk-s-sam-technology-could-revolutionise-vaccines/ https://www.gsk.com/en-gb/behind-the-science/innovation/stem-inspiring-real-world-scientists/ https://www.gsk.com/en-gb/behind-the-science/innovation/revealing-the-beautiful-complexity-of-the-immune-system/ https://www.gsk.com/en-gb/behind-the-science/innovation/the-lung-microbiome-and-the-future-management-of-respiratory-disease/ https://www.gsk.com/en-gb/behind-the-science/innovation/why-collaboration-is-essential-to-achieving-new-breakthroughs-in-vaccines/ https://www.gsk.com/en-gb/behind-the-science/innovation/immuno-oncology-integrating-innovation-into-standard-of-care-practice/ https://www.gsk.com/en-gb/behind-the-science/innovation/looking-deeper-into-lupus/ https://www.gsk.com/en-gb/behind-the-science/innovation/30-years-and-counting-the-fight-against-hiv/ https://www.gsk.com/en-gb/behind-the-science/innovation/inclusive-design-making-our-differences-invisible/ https://www.gsk.com/en-gb/behind-the-science/innovation/using-vaccine-science-to-combat-antimicrobial-resistance/ https://www.gsk.com/en-gb/behind-the-science/innovation/following-the-science-of-oxygen-to-discover-solutions-for-anaemia/ https://www.gsk.com/en-gb/behind-the-science/our-people/ https://www.gsk.com/en-gb/behind-the-science/our-people/the-science-of-shopping/ https://www.gsk.com/en-gb/behind-the-science/our-people/beyond-manufacturing-in-chile-and-madagascar/ https://www.gsk.com/en-gb/behind-the-science/our-people/the-design-behind-the-device/ https://www.gsk.com/en-gb/behind-the-science/our-people/how-curious-minds-saved-a-medicine-from-being-left-in-the-lab/ https://www.gsk.com/en-gb/behind-the-science/our-people/i-control-my-asthma-it-doesn-t-control-me/ https://www.gsk.com/en-gb/behind-the-science/our-people/making-the-ellipta-inhaler-a-reality/ https://www.gsk.com/en-gb/behind-the-science/our-people/following-the-journey-of-a-respiratory-medicine/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/eggs-in-manufacturing/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/living-with-lupus-a-patient-perspective/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/an-everyday-world-first-in-clinical-trials/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/don-t-forget-the-pharmacists/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/can-social-media-help-us-hear-patients/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/giving-a-bit-back-christine-s-experience-of-clinical-research/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/does-lupus-really-know-no-boundaries/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/youll-outgrow-some-childhood-habits-but-vaccination-is-for-life/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/thank-you-for-calling-gsk-meet-paul-the-voice-at-the-end-of-the-line/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/overcoming-the-challenges-of-copd-to-fulfil-a-lifelong-dream/ https://www.gsk.com/en-gb/behind-the-science/patients-consumers/copd-for-john-just-means-doing-everything-at-a-slower-pace/ https://www.gsk.com/en-gb/terms-of-use/ https://www.gsk.com/en-gb/terms-of-use/overview/ https://www.gsk.com/en-gb/terms-of-use/global-eula-for-mobile-apps-using-pii/ https://www.gsk.com/en-gb/terms-of-use/global-eula-for-mobile-apps-not-using-pii/ https://www.gsk.com/en-gb/business-to-business/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/active-pharmaceutical-ingredients/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/steriles-and-clean-liquids/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/antibiotics/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/solid-dose/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/platform-technologies/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/inhalation/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/biopharm/ https://www.gsk.com/en-gb/business-to-business/contract-manufacturing/foams-liquids-and-topicals/ https://www.gsk.com/en-gb/business-to-business/discovery-and-development-consulting/ https://www.gsk.com/en-gb/business-to-business/discovery-and-development-consulting/development-insight/ https://www.gsk.com/en-gb/business-to-business/discovery-and-development-consulting/technical-approaches/ https://www.gsk.com/en-gb/business-to-business/discovery-and-development-consulting/open-innovation/ https://www.gsk.com/en-gb/accessibility/ https://www.gsk.com/en-gb/cookie-policy/ https://www.gsk.com/en-gb/gsk-employees/ https://www.gsk.com/en-gb/privacy-notice/